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I. Abstracts 
I.1. Zusammenfassung 
Krebsimmuntherapie ist eine viel versprechende Alternative zu den konventionellen 
Therapien, wie Bestrahlung, chirurgische Entfernung des Tumors oder klassische 
Chemotherapie. Der größte Vorteil der Krebsimmuntherapie ist Spezifität, welche 
durch das Zielen des Immunsystems auf so genannte Tumor-Assoziierte Antigene 
erreicht wird. Diese Form der Therapie sollte weniger Nebenwirkungen als 
Standardbehandlungen beinhalten, weiterhin könnte diese Metastasen an Orten fern 
des eigentlichen Tumors bekämpfen. Krebsimmuntherapie zeigte sich jedoch wenig 
erfolgreich in späten klinischen Studien. Zusätzlich ist die Mortalitätsrate bei 
Krebsleiden, trotz allen Fortschritts, immer noch sehr hoch, weshalb die 
Notwendigkeit der Entwicklung alternativer Immuntherapien besteht.  
Ein interessanter Ansatz hierzu ist die Verwendung von Bakterien wie attenuierten 
Salmonellen als Träger heterologer Krebsantigene. Eine Vielzahl präklinischer 
Studien zeigte, dass Vakzine auf der Basis von Salmonellen CD4 und CD8 positive 
zelluläre Immunantworten auslösen können, welche für eine Krebsimmuntherapie 
entscheidend sind. Spezielle Antigenliefersysteme in Salmonellen, wie die 
oberflächengebundene Expression oder die Sekretion von Antigenen sind von Vorteil 
für die Immunogenität der Antigene. 
Diese Arbeit zielte auf die Entwicklung von neuen Salmonella Trägerstämmen für die 
Immuntherapie gegen Krebs. Im ersten Projekt wurde TolC, ein multifunktionelles 
Protein der E. coli Außenmembran, als Membrananker für drei heterologe Antigene 
benutzt um eine oberflächenassoziierte Expression dieser Antigene zu erreichen. Die 
entsprechenden plasmidkodierten TolC Fusionsproteine wurden hinsichtlich ihrer 
Expression, Funktionalität und Plasmidstabilität in verschiedenen, rekombinanten 
Salmonella Stämmen in vivo und in vitro untersucht. Die Menge an 
membranständigem rekombinanten TolC war stark erhöht in tolC-deletierten 
Stämmen. Zusätzlich waren die Fusionsproteine funktionsfähig und die Plasmide 
wurden in vitro und in vivo äußerst stabil vererbt. Leider konnten weder spezifische 
CD4+/CD8+ T-Zellantworten gegen das Modelantigen Ovalbumin noch CD8+ 
Antworten gegen das Krebsantigen BRAFV600E in immunisierten Mäusen detektiert 
werden. Mäuse, die mit einem Salmonella Stamm immunisiert wurden, der ein 
immundominantes Epitop des krebsassoziierten Prostata spezifischen Antigens 
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(PSA) in oberflächengebundener Form produziert, waren jedoch partiell vor PSA 
exprimierenden Melanomzellen geschützt. Das Tumorwachstum in diesen Mäusen 
verlief signifikant langsamer als in Kontrollgruppen, was indiziert, dass dieses System 
schützende Immunantworten gegen Krebs auslösen kann. 
 
In einem zweiten Projekt wurde der zur Typhusimpfung zugelassene Stamm 
Salmonella enterica serovar Typhi Ty21a (Ty21a) für die Hämolysin Sekretion 
verbessert. Dieses aus E. coli stammende Typ I Sekretionssystem wurde oftmals für 
die Sekretion von heterologen Antigenen in lebenden bakteriellen Impfstoffträgern 
verwendet. In dieser Arbeit wurde gezeigt, dass eine Mutation von rpoS in Ty21a mit, 
im Vergleich zu anderen Salmonellen, verminderter Sekretionsfähigkeit von 
Hämolysin korreliert. Komplementation von rpoS oder rfaH, einem vermuteten 
Zielprotein von rpoS in Ty21a, verbesserte die Expression und Sekretion von 
heterologem Hämolysin. RfaH-rekombinante Salmonellen stimulierten höhere 
Serumantikörpertiter gegen Hämolysin in immunisierten Mäusen als vergleichbare 
Kontrollen und sogar rpoS komplementierte Salmonellen, vermutlich durch eine 
Erhöhung der Menge an freiem Hämolysin. Daher könnte dieser Stamm die Basis 
einer neuen Generation von Impfstämmen gegen heterologe (Krebs-) Antigene für 
den humanen Gebrauch bilden. 
 
I.2. Abstract 
Cancer immune therapy represents a promising alternative to conventional anti 
tumour therapy like radiation, surgical excision of the tumour or classical 
chemotherapy. The biggest advantage of cancer immune therapy is specificity, 
achieved by targeting tumour-associated antigens with the effector arms of the host 
immune system. This is believed to result in less adverse effects than standard 
therapy and reaches presumably also metastatic lesions at distant sites from the 
primary tumour. However, cancer immune therapy by vaccination against tumour 
antigens failed to translate into clinical success, yet. Furthermore, despite 
tremendous clinical efforts malignant disease still results in high mortalities giving rise 
to the need for novel vaccination-based therapies against cancer. 
An interesting approach in this respect is the use of bacteria like attenuated 
salmonellae as carriers for heterologous cancer antigens. In numerous preclinical 
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studies Salmonella-based vaccines could elicit cell mediated immune responses of 
the CD4+ and CD8+ type against own and heterologous antigens which make them 
ideally suited for anti tumour therapy. Special delivery systems in Salmonella carriers 
like surface display or secretion of antigens were shown to be advantageous for the 
immunological outcome.  
This work focussed on developing novel Salmonella carriers for immune therapy 
against cancer. In a first project, TolC, a multifunctional outer membrane protein of E. 
coli was utilized as membrane anchor for 3 heterologous antigens. Respective TolC 
fusion proteins encoded on plasmids were analysed for expression, functionality and 
plasmid stability in different engineered Salmonella strains. The amount of membrane 
localized recombinant TolC was enhanced in tolC-deficient strains. Furthermore, 
fusion proteins were functional and plasmid stability was very high in vitro and in vivo. 
Disappointingly, neither specific CD4+/CD8+ T-cell responses against the model 
antigen ovalbumin nor CD8+ responses against the cancer antigen BRAFV600E were 
detectable in murine model systems. However, mice immunized with Salmonella 
strains displaying an immunodominant epitope of the cancer related prostate specific 
antigen (PSA) were partially protected from subsequent tumour challenge with a PSA 
expressing melanoma cell line. Tumour growth in mice immunized with the respective 
strain was significantly decelerated compared to controls, thus indicating that this 
surface display system confers protective immunity against tumours.  
 
In a second study, the approved typhoid vaccine strain Salmonella enterica serovar 
Typhi Ty21a (Ty21a) was improved for the hemolysin type I secretion system of E. 
coli. This secretion system is widely used for heterologous antigen delivery in live 
bacterial vaccines. It was demonstrated throughout this work that a mutation of rpoS 
in Ty21a correlated with decreased ability for hemolysin secretion compared to other 
Salmonella strains. Complementation with rpoS or the presumed downstream target 
of rpoS, rfaH resulted in enhanced expression and secretion of heterologous 
hemolysin in Ty21a. Presumably by raising the amount of free antigen, rfaH-
complemented Ty21a elicited higher antibody titres against heterologous hemolysin 
in immunized mice than controls and even rpoS-positive Ty21a. Therefore, rfaH-
complemented Ty21a could form the basis of a novel generation of vaccines for 
human use based on (cancer) antigen secretion. 
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II. Introduction 
II.1. Cancer immune therapy 
II.1.1. Cancer 
Cellular transformation is initiated by genetic and epigenetic mutations that activate 
oncogenes and inactivate tumour suppressor pathways (1). The path of cancer thus 
requires that somatic cells escape from various intrinsic tumour suppressor 
mechanisms that prevent cell cycle progression. In addition, transformed cells lose 
their responsiveness to extrinsic signals afforded by the extracellular matrix and the 
neighbouring cells that normally operate to maintain tissue homeostasis. Cancer thus 
arises when somatic cells acquire pro-mitotic signals and escape intrinsic and 
extrinsic suppressor mechanisms in the context of their cellular microenvironment (2). 
Furthermore, cancer cells can break away from the malignant solid tumour and 
spread to distant parts of the body (3). Cancer malignancies are among the most life-
threatening diseases in industrialized countries. Although classical cancer therapies, 
including surgical resection of the primary tumour, radiation and chemotherapy, are 
well established, cancer still causes 25 % of mortalities. Annually, about 1 % of the 
population that has been diagnosed with cancer, die. Five-year survival rates range 
from 10-20 % for lung, oesophagus and stomach cancer, to 40-60 % for colon, 
bladder and cervix cancer, and 60–80 % for breast and prostate cancer (4). One 
reason for this is that dysfunctional tumour suppressor genes are selected in the 
course of standard chemotherapy leading to relapse of the disease highly resistant to 
conventional treatment (2). These facts emphasize the need for novel anti cancer 
therapies.  
 
II.1.2. The idea of cancer immune therapy 
One of these novel therapeutic approaches which gained attention in the past 
decades is referred to as cancer immune therapy. It has become evident that the 
development of cancer does not progress unnoticed by the immune system and 
immunity can prevent the occurrence of tumours. This concept has been named 
“immunosurveillance” and several mouse models together with clinical data have 
unambiguously demonstrated its role as an effective tumour suppressor mechanism 
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(5,6) suggesting that the effector arms of the immune system are able to mediate 
tumour regression. It is estimated that immune therapy has less side effects 
compared to standard therapies such as chemotherapy or radiotherapy (7). On the 
other hand, cancer immune therapy has been proposed as therapeutic intervention to 
boost or elicit immune responses in patients with minimal residual disease e.g. after 
surgical excision of the primary tumour before recurrence of cancer at metastatic 
sites (8). However, the first clear indication for effective immune therapy, the 
administration of high dose of interleukin-2 (IL-2), was able to mediate regression of 
even bulky, invasive tumours in selected patients with melanoma, kidney cancer and 
non-Hodgkin’s lymphoma (9).  
 
Multiple studies have been undertaken to clarify the nature of protective immunity 
observed in animal models and it could be shown that cellular rather than humoral 
immune responses were responsible for the rejection of transplanted tumours (10). 
Thus, significant effort has been made towards the identification of antigens 
recognized by human T-lymphocytes (11-13). Both, CD8+ cytotoxic T-cells and CD4+ 
T-helper cells recognize antigens presented as small peptides in the groove of 
surface human leukocyte antigen (HLA, the human analogue of the major 
histocompatibility complex (MHC)) molecules. CD8+ cells recognize peptides of 8-10 
amino acids length, derived from intracellular cytoplasmic proteins, digested in 
proteasomes and presented via the endoplasmatic reticulum on cell surface class I 
HLA (or MHC) molecules. In contrast, CD4+ cells use a different intracellular pathway 
and present engulfed extracellular proteins, digested to peptides in intracellular 
endosomes and presented on cell surface class II HLA (or MHC) molecules (10). In 
principle, cancer immune therapy employing T-cells can be achieved in two ways: (i) 
the adoptive transfer of ex-vivo activated T-cells or (ii) in vivo activation by the use of 
cancer vaccines. As this work deals with vaccination therapy the following sections 
focus on vaccine-based cancer immune therapy knowing that adoptive transfer of T-
cells, the administration of adjuvants for cancer immune therapy and antibodies 
against extracellular receptors e.g. Rituxan and Herceptin reached the clinics (14-16). 
The unique advantage of vaccination-based cancer immune therapy is specificity as 
the immune system is able to recognize epitopes of antigens that are expressed by 
tumour cells and target those cells for destruction without harnessing normal ones. 
Those antigens determining specificity were termed tumour-associated antigens. 
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II.1.3. The cellular basis of cancer immune surveillance 
Tumour associated antigens (TAAs) can be segregated into five categories: (i) 
differentiation antigens e.g. melanocyte differentiation antigens (in melanoma) like 
Melan-A/MART-1, tyrosinase and gp-100; (ii) mutational antigens, e.g. abnormal 
forms of p53; (iii) overexpressed/amplified antigens, e.g. HER-2 neu (breast cancer) 
(iv) cancer testis antigens e.g. MAGE and NY-ESO (germ line tumours, sarcomas 
malignant melanomas), normally expressed only in the germ line, notably the testis, 
but also abundant in various cancer cells; and (v) viral antigens, e.g. EBV and HPV 
(cervix carcinoma) (11,17,18). Epitopes of TAAs are recognized by T-cells. The 
activation of antigen specific CD8+ T-cells can depend on interaction with CD4+ but 
the final effector cell in most mouse models is the CD8+ cytotoxic T-cell (CTL). 
Perforin-mediated cytotoxicity and Fas/Fas ligand interaction are major mechanisms 
for CD8+ T-cell-mediated effector function (19,20). After the TCR engages specific 
antigenic peptides presented by the MHC (or HLA) of target cells, perforin is released 
and causes damage to target cell membranes. Various granzymes and possibly other 
granule constituents co-secreted with perforin enter the target cell and induce 
apoptosis (21). The expression of a variety of cytokines, including Fas ligand (FasL) 
is also enhanced in T-cells after antigen specific activation. FasL cross-links Fas on 
the target cells and in many cells this interaction triggers apoptosis and cell death 
(20). Studies in perforin-deficient mice showed that perforin-mediated cytotoxicity is 
essential for resistance against injected tumour cell lines, viral and chemical 
carcinogenesis as well as spontaneous leukemogenesis (21-23). Although the role of 
Fas dependant cancer cell death was reported to play only a minor role, there are 
hints on FasL mediated cancer rejection of tumour cells which are responsive to this 
pathway (24).  
Additionally, most effective antitumour immune responses in animal models depend 
on the efficient generation of CD4+ T-helper 1 cell (Th 1) immunity that promotes CTL 
responses (8) in contrast to Th 2 helper cells which trigger the humoral immune 
system. The importance of Th 1 helper cells is also strengthened by the fact that 
progressive neoplastic disease is characterized by a response that is skewed 
towards Th 2 cells (25). Among the Th 1 cytokines, Interferon (IFN) γ seems to play a 
crucial role for alarming the immune system and cancer cell cytotoxicity (6).  
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However, classical CD8+ T-cells are not the only source of IFNγ and mediators of 
cytolysis. Components of the innate immune system also participate in the process of 
immunosurveillance. NKG2D is a lectin-like receptor expressed by natural killer cells 
(NK), γδ T-cells, some CD8+ T-cells and natural killer T-cells (NKT) (26). NKG2D 
ligands are often ectopically expressed in a wide range of murine tumours (27) and 
human carcinomas of lung, kidney, prostate, ovary, colon (28), liver (29) as well as 
melanoma (30). Tumour cells can therefore be recognized by immune cells via the 
NKG2D receptor which lead to tumour repressive functions in vivo e.g. by IFNγ 
secretion of γδ T-cells (31). Additionally, tumour necrosis factor related apoptosis 
inducing ligand (TRAIL) can engage the TRAIL-R2 receptor in mice and induce 
cytolysis via apoptosis. TRAIL is expressed on a subset of liver NK cells and is 
induced by interferons in NK cells, monocytes and dendritic cells (DCs) (32) 
representing another mechanism employed by the innate immune system to kill 
cancer cells.  
 
II.1.4. Strategies, challenges and limitations for cancer vaccines 
Attempts at immunotherapy of cancer have included vaccination with viral vectors 
(33,34), antigenic synthetic peptides (35,36), antigen loaded DCs (37,38) and DNA 
encoding tumour-associated antigens (39). All approaches have their own 
advantages and disadvantages but the biggest challenge for every type of anti-
cancer vaccination is tolerance as all cancer antigens are self antigens and even 
large numbers of tumour-infiltrating, specific T-cells may fail to mediate tumour 
regression (40,41). This “anergy” needs to be overcome and therefore basically all 
cancer vaccines employ adjuvants, whether they are composed of whole cells, 
defined proteins or peptides and other molecules (8). Adjuvants can activate antigen 
presenting cells to stimulate T-cells more efficiently or activate NKs and other cells of 
the innate immune system to produce cytokines or promote survival of antigen 
specific T-cells (8). For example, cytokines like IL-2, granulozyte-macrophage colony 
stimulating factor (GM-CSF), IL-12, IL-4 and several others have been used as 
adjuvants in cancer vaccines (42). Two classes of adjuvants even facilitate delivery of 
antigens into the cytoplasmic compartment of antigen presenting cells (APCs) to 
trigger predominantly CD8+ responses: (i) PLGA microspheres and virus like particles 
(43) as well as (ii) immunostimulatory complexes (ISCOMs), a mixture of QuilA and 
cholesterol that forms micelles (44).  
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A phenomenon that could form possible obstacles for efficient immune therapy was 
referred to as cancer “immunoediting”. This term describes the fact that the immune 
system is sculpting tumours which in turn could lead to immune escape of cancer 
cells. Tumour immune escape mechanisms involve cellular and molecular processes. 
Analysis of human tumour specimens has shown that many display losses of HLA 
class I proteins (45,46). In addition, tumour and tumour stroma cells were identified to 
secrete immune suppressive factors like IL-10 and TGF-β (47) or soluble forms of 
NKG2D ligands (28) which attenuate innate and adaptive immune responses against 
cancer cells. Recently, populations of immunosuppressive cells have been identified 
which were generated or activated by tumour cells. Among them are IL-13 producing 
NKT cells (48) and CD4+ CD25+ regulatory T-cells (Tregs), the latter shown to be 
responsible for the failure to reject transplanted tumours in the murine host (49,50). A 
third class of immune-suppressive immune cells is represented by myeloid-derived 
suppressor cells (MSCs) which inhibit CD8+ T-cell functions and trigger T-cell 
apoptosis in response to IFNγ release (51). An often critical but underappreciated 
point deals with the aging immune system. As most cancer patients are of advanced 
age, many years after the thymus stopped producing naïve T-cells, immune 
responses may be hindered. It was clearly shown in mouse models that generation of 
the primary response to antigen and the conversion to memory is compromised with 
age (52,53). Finally, apart from melanoma therapeutic cancer vaccination till now 
failed to translate into convincing clinical response in late stage trials (54,55), further 
underscoring the need for novel immune-stimulating therapies. 
 
II.1.5. Bacteria and cancer: hallmarks for bacterial cancer immune 
therapy  
As tumours or metastases develop, they stimulate angiogenesis to promote the 
formation of new blood vessels. However newly formed vessels are highly 
disorganised with incomplete endothelial linings and blind ends, resulting in inefficient 
nutrient and oxygen delivery to those neoplastic tissues (56). This leads to multiple 
regions of hypoxia and anoxia within tumours (57). Furthermore, these areas are 
believed to represent niches where immunological clearance mechanisms are absent 
(56), thus creating a favourable environment for the growth of obligate and facultative 
anaerobic bacteria. Indeed, it was shown that different bacteria like Clostridia, 
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Salmonella, Vibrio and Bifidobacterium can infiltrate, replicate and then preferentially 
accumulate in tumours (58-61). This tumour-targeting feature of bacteria gave rise to 
several clinical options. For example, Clostridia spores injected into mice harbouring 
transplanted sarcomas resulted in vegetative growth of those bacteria inside necrotic 
areas and finally oncolytic regression of the tumour (62,63). Another approach is the 
use of tumour-infiltrating bacteria as vehicles to deliver cytotoxic proteins or nucleic 
acids encoding them (61,64-66) to allow cancer targeted therapy with the aim of 
reducing adverse effects and achieving treatment “in situ”. 
More interesting with respect to cancer immune therapy are historical findings of the 
surgeon W.B. Coley. He observed that when patients suffering from sarcomas 
developed acute streptococcal infections, their tumours regressed, due to the 
stimulation of the innate immune system (67). More recently, despite their known 
oncolytic activity, Clostridia were found to eradicate tumours due to induction of the 
inflammatory response and generation of CD8+ T-cells reactive to cancer cells in 
experimental animal models (68). Furthermore, bacterial products, like 
lipopolysaccharide (LPS) or unmethylated CpG dinucleotide-containing bacterial DNA 
have been used for many years as effective adjuvants. These bacterial compounds 
are particularly good in activating CTLs, thus being of interest for tumour 
immunologists (69). Bacterial products stimulate pattern recognition receptors 
expressed by DCs, macrophages and perhaps NK cells and other cells of the innate 
system. This induces their maturation, activation and production of pro-inflammatory 
cytokines (8). Many of these receptors belong to the family of Toll-like receptors 
(TLRs) that are located either on the surface or inside cells and recognize invading 
pathogens (70).  
For those reasons, the use of attenuated live bacterial vaccines (LBV) represents an 
interesting alternative for cancer immune therapy. They stimulate innate responses 
as well as adaptive immunity. This and the ability to express foreign proteins make 
them ideal vectors for vaccination against tumour-associated antigens. Features of 
live bacterial vaccines and immune responses elicited by those vectors are discussed 
in depth in the following sections. 
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II.2. Live bacterial vaccines 
II.2.1. General features of live bacterial vaccines 
Live attenuated bacterial vaccines are able to elicit immune responses against own 
antigens and confer protection towards challenge with virulent bacteria. As 
mentioned above, LBV can also be used for the delivery of heterologous antigens 
and these vectors offer many potential clinical advantages: (i) they are easy and 
relatively inexpensive to produce (ii) they are also well-suited to large scale 
manufacture and potentially stable without refrigeration (via lyophilization), (iii) are 
able to carry large or multiple antigens or adjuvants (iv) and can be eradicated with 
antibiotics should the need arise (71). Delivery of vaccine antigens by LBV via the 
mucosal route results in the elicitation of effective humoral and cellular responses at 
the level of both systemic and mucosal compartments, not only at the specific 
inductive site but also at remote mucosal sites (72-74). Mucosal (oral) delivery 
comprises further advantages like high acceptance, easy administration and 
amplification of the carrier at mucosal sites leading to persistent antigen production 
(75). LBV induce the production of multiple cytokines, including Th 1 cytokines like 
TNFα, IFNγ and IL-12 and inflammatory mediators such as nitric oxide which 
enhance early innate immunity and create a local environment favourable to antigen 
presentation (76). There are currently three live bacterial vaccines licensed for 
human use: (i) Salmonella enterica serovar Typhi Ty21a (Ty21a), (ii) Vibrio cholerae 
CVD 103-HgR and (iii) Mycobacterium bovis BCG (BCG). These strains among 
others have been used as vectors to express heterologous antigens and were 
evaluated in numerous animal models, albeit there are no clinically used LBV in this 
respect (71). 
 
II.2.2. Salmonella typhi Ty21a: vaccine and vaccine vector 
Attenuated Salmonella strains were among the first bacteria used as recombinant 
vectors for antigen delivery (77). A prominent example is Ty21a which was isolated in 
the early 1970s by chemical mutagenesis of its respective wildtype S. typhi Ty2 as 
vaccine against typhoid fever in humans. It has a GalE and Vi negative phenotype 
(78). The mutation of the galE gene results in a complete deficiency of the enzyme 
uridine diphosphate (UDP)-galactose-4-epimerase, which is responsible for the 
conversion of UDP-glucose to UDP-galactose and vice versa. Since galactose is 
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incorporated into the lipopolysaccharide (LPS) core moiety via UDP-galactose, the 
absence of galE leads to the formation of rough LPS, devoid of parts of the core and 
the O-antigen. As the O-antigen is the main antigenic determinant on the cell surface, 
Ty21a is supplied with a source of external galactose during production of the 
vaccine. This enables the bacteria to generate UDP-galactose by an alternative 
route, thereby expressing complete immunogenic LPS. Albeit the immunogenic 
capacity is maintained under appropriate growth conditions, the galE phenotype 
contributes to strain attenuation in vivo (76). As a result of the mutagenesis method 
used, Ty21a acquired further spontaneous mutations including via and ilvD genes, 
leading to the loss of Vi polysaccharide and an auxotrophic phenotype for isoleucine, 
respectively and a mutation precluding H2S utilisation (79). 
Interestingly, an additional mutation in the rpoS gene, which also contributes to the 
avirulence of the Ty21a strain (80) was inherited from the wildtype parental strain 
Ty2. This mutation is apparently one of the reasons for the poor capacity of Ty21a to 
survive starvation conditions and resist various environmental stress conditions (81). 
This, combined with the low shedding rate (82), reduces the environmental risks 
posed by use of Ty21a. Ty21a conferred protection against typhoid fever in 70-80 % 
of vaccinees (83) accompanied by only mild and infrequent adverse effects (84). 
Additionally, the multiple mutations render Ty21a genetically stable, thus reversion to 
virulence has neither been observed in vitro nor in vivo (85). The well documented 
safety makes Ty21a an attractive carrier for antigen delivery and this has been 
undertaken in several clinical trials encompassing heterologous bacterial antigens 
(86-89).  
Salmonella typhi strains are human pathogens and restricted to the human host. 
Mice are intrinsically resistant to S. typhi, particularly if administered orally (90). 
However, mice are susceptible to serovar Typhimurium infection developing a 
typhoid-like disease (91), therefore murine Salmonella enterica serovar Typhimurium 
infection serves as model for S. typhi pathogenesis. Furthermore, serovar 
Typhimurium attenuated mutants were assessed as vaccine carriers in various 
mouse models for antigens derived from other bacteria, viruses, parasites and 
tumours, being able to stimulate strong systemic and local immune responses 
against the corresponding antigens (reviewed in (92)). Nevertheless, Ty21a was 
found to be immunogenic in mice when applied intranasally (93), thus this model can 
be used for preclinical evaluation of Ty21a based vaccines. 
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II.2.3. Immune responses elicited by Salmonella 
Development of immunity to Salmonella infection relies on the cellular, humoral and 
mucosal arms of the immune system (94). The concerted action of several cytokines 
like TNFα, IFNγ, IL-12, IL-15 and IL-18, cellular compounds of the innate immune 
system like DCs, macrophages and NK cells but also humoral and T-cell responses 
are essential for the adaptive phase of the immune response and for controlling later 
stages of Salmonella infection (reviewed in (95)). Initiation of an immune response 
usually involves DCs, the most important professional antigen presenting cells, which 
are capable of priming naïve T-cells (96). Salmonella infect DCs in vivo and in vitro 
and can induce activation of and cytokine production by those cells (97-99).  
Following immunization with protective live attenuated Salmonella vaccines, long-
lasting immunological memory develops in animals and humans (95). Cellular 
responses towards Salmonella vaccines are of the Th 1 type (100,101). Ty21a in 
particular, induced strong CD4+ Th 1 responses in human vaccinees, characterized 
by the production of IFNγ in the absence of IL-4 but also humoral responses like 
potent induction of IgG and mucosal IgA type antibodies (102). Vaccination with 
Ty21a also elicited strong CD8+ CTL responses which persisted for at least 2 years 
after immunization. A strong correlation was found between the CTL activity and the 
frequency of IFNγ-secreting CD8+ T-cells (103). When administered intranasally, 
serovar Typhi vaccines were also found to elicit CD8+ responses in the murine host 
(104). Initial studies with live attenuated Salmonella typhimurium showed a clear 
elicitation of CTL responses against a passenger circumsporozoite antigen of 
Plasmodium berghei after oral immunization in mice, furthermore these responses 
were protective (105). CD8+ T-cell responses due to Salmonella encounter are 
surprising as these bacteria reside within defined cellular compartments of 
professional APCs rendering the classical MHC class I pathway unlikely for antigen 
presentation. However, a process termed cross-presentation explains CD8+ 
responses after Salmonella infection by an alternative class I processing pathway for 
exogenous phagocytic antigens (106,107).  
Taken together, live attenuated salmonellae exhibit exactly the immune-stimulatory 
properties which are needed for a TAA-directed immune therapy of cancer (see 
II.1.3). Efficient stimulation of immune responses against heterologous antigens 
relies on proper transfer of antigen into APCs. This is achieved by LBV utilizing 
special delivery systems introduced in the following. 
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II.2.4. Antigen localisation and antigen delivery systems 
Earlier studies have shown that the localization of the antigen within a live bacterial 
vaccine plays a critical role for the immunological outcome. Secretion of an antigen 
into the extracellular medium or expression on the outer surface of a vaccine carrier 
appears to be advantageous in eliciting immune responses. Kang et al. showed that 
the secreted form of Streptococcus pneumoniae PspA elicited a 104 fold increase in 
IgG antibody titres compared with cytoplasmic expressed antigen when delivered via 
attenuated Salmonella typhimurium in mice (108). Several other studies proved this 
superior immunological capacity of secreted versus cytoplasmic antigen delivery 
(109-111). One of the best studied secretion systems for antigen delivery is the E. 
coli α-hemolysin secretion system (112). This transport machinery is the prototype of 
type I secretion systems and consists of three different components: HlyB, HlyD and 
TolC. The HlyA carries a secretion signal, 50-60 amino acids in length at its C-
terminus (HlyAs) which is recognized by the HlyB/HlyD/TolC translocator leading to 
direct secretion of the entire protein into the extracellular medium without periplasmic 
intermediates. Dozens of antigens of bacterial, parasitic and viral origin have been 
fused to the HlyAs and efficiently secreted within Salmonella vaccine vectors. These 
strains showed promising results in diverse animal model systems referring to 
protection against pathogen challenge or induction of humoral and cell-mediated 
immunity (112,113). Recently, our group demonstrated in two separate preclinical 
studies that live attenuated Salmonella typhimurium were able to induce protective, 
antigen-specific CTL responses against different tumour-associated antigens 
delivered via the hemolysin secretion system (114,115).  
Another antigen delivery mechanism utilizes the type III secretion system in 
Salmonella vaccine carriers which allows translocation of proteins into the cytoplasm 
of APCs and therefore directly to the MHC class I restricted antigen processing 
pathway (116,117). Rüssmann et al. demonstrated that a hybrid protein 
encompassing the type III secreted effector protein SptP and the CD8+ epitope of the 
murine lymphocytic choriomeningitis virus (MCLV) nucleoprotein was efficiently 
secreted into the host cytosol and induced potent CTL responses leading to complete 
protection against a lethal intracerebral challenge with the virulent virus in orally 
immunized mice (118). This system was also successfully applied in a murine 
fibrosarcoma model (119). 
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Display of proteins or peptides on the bacterial surface can be mediated in several 
ways (for review see (120)) and became interesting for vaccinology as it was shown 
that surface-anchored antigens also elicit stronger immune responses than antigens 
expressed in cytoplasmic fashion. For this purpose, antigens were fused into different 
outer membrane proteins or membrane attached autotransporter domains. For 
example, the autotransporter domain of the E. coli adhesion molecule AIDA-I was 
applied for surface display of nearly full length or T-helper epitopes of the H. pylori 
UreA protein on a Salmonella carrier. These strains were more protective towards 
challenge with H. pylori than Salmonella expressing UreA antigens in the cytoplasm 
(121). The outer membrane-localized ice nucleation protein of Pseudomonas 
syringae was successfully utilized as carrier for hepatitis antigens in Ty21a and found 
to elicit higher antibody responses in mouse serum than a similar system relying on 
intracellular antigen expression (122). Other methods similar to these approaches 
were based on fusions to outer membrane proteins like the flagella protein FliC of 
Salmonella (123,124), E. coli derived p87 fimbriae (125), LamB (126) and TolC (127). 
 
II.3. Objectives – part I 
II.3.1. Surface display of antigens via TolC 
The first project of the present thesis aimed at developing new recombinant 
Salmonella vaccine strains for immune therapy of cancer. Therefore, we decided to 
apply an existing plasmid-encoded vaccination system based on surface display of 
antigens, for its capacity in a tumour vaccination setting. In the mentioned study 
(127), the outer membrane protein TolC of E. coli was utilized as membrane anchor 
for CD4+ T and B-cell epitopes of the p60 protein from Listeria moncytogenes and 
transferred into the Salmonella enteriditis SM6T strain, lacking endogenous tolC. The 
TolC fusion protein (TolC-LisTB) was stably expressed and functional in SM6T and 
elicited immune responses that were protective against lethal Listeria challenge in 
mice.  
TolC is a trimeric pore-forming protein in the outer membrane of E. coli (6) with 
structurally conserved homologs in virtually all gram-negative bacteria (for a list see 
(128)). TolC is one of the most multifunctional proteins known in gram-negative 
bacteria: it is essential for type I secretion of hemolysin and colicin V, import of colicin 
E1 and serves as receptor for phages U3 and TLS (for review see (129,130)). A 
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clinically relevant role of TolC is its involvement in multidrug efflux, rendering bacteria 
insensitive towards a wide variety of non-related noxious compounds. The most 
important efflux system in E .coli and Salmonella consists of the inner membrane 
complex AcrA/AcrB recruiting TolC as outer membrane channel. This tripartite 
machinery expels antimicrobials directly into the extracellular compartment inhibiting 
intracellular accumulation of toxic drugs (131-133). Apart from multidrug efflux, a role 
for TolC in pathogenesis of gram-negative bacteria is discussed (134). The crystal 
structure of TolC, elucidated by Koronakis et al. (135), shows that a TolC homotrimer 
forms a channel tunnel 140 Å in length, that comprises a 100 Å long α-helical barrel 
(the tunnel domain) anchored in the outer membrane by 12 stranded β-barrel spans 
(the channel domain). The larger part of the protein is located in the periplasm; only 
two small loops (amino acid residues (aa) 52–61 and 257–279) are exposed on the 
surface of the bacteria.  
 
 
 
Figure II.1 Overview of TolC structure and antigen insertion site (taken from (135) and Andersen, C 
unpublished, abridged) 
Left panel: TolC forms a homotrimer with the larger part projecting into the periplasm; the channel 
domain (yellow) is located in the outer membrane. Two loops are protruding outside the bacterium 
(ring-tagged and lower right panel) 
Right panel: Schematic view on surface exposed loops of one TolC monomer. The investigated 
antigens were inserted within the loop comprising aa 257-279.  
 
The loop comprising aa 257-279 contains a unique KpnI restriction site allowing 
genetic insertion of antigens into this permissive, surface-exposed structure (127). A 
structural view of TolC trimers and a schematic picture of the antigen insertion site 
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within the surface exposed loop are depicted in Figure II.1. To investigate the 
established system for its capacity to protect from neoplastic disease, novel 
attenuated Salmonella strains were constructed. Ty21a and S. enterica serovar 
Typhimurium aroA SL7207 (Stm) were deleted for their chromosomal tolC. Three 
different antigens were subject of the present work, among them, chicken ovalbumin 
which served as model antigen, furthermore BRAFV600E and PSA that represent 
tumour-associated antigens. Construction of plasmids encoding ovalbumin and 
BRAF epitopes fused to the TolC loop are described in this study. Construction and 
characterization of the TolC-PSA fusion was accomplished earlier (136). 
Recombinant TolC proteins were assessed for functionality in the different 
Salmonella tolC phenotypes to explore viability of those novel engineered vaccine 
strains. Finally, recombinant strains were tested in various animal model systems for 
their capacity to induce T-cell responses and to confer protection against antigen 
expressing tumour xenografts. The respective antigens and their cognate epitopes 
are described in more detail in the following sections. 
 
II.3.2. Displayed antigens – Ova 
In a first approach, we aimed to elucidate the kind of T-cell response elicited by 
recombinant Salmonella employing the TolC-based antigen expression system. 
Chicken ovalbumin (Ova) was selected to serve as model antigen due to its defined 
epitope structure for mice of the H-2b haplotype and existence of mouse models 
transgenic for TCRs recognizing cognate Ova epitopes (137,138). As the loop 
structure is spatially limited, the class I and class II restricted epitopes of ovalbumin 
were inserted into tolC and assessed in adoptive transfer models well established for 
investigation of T-cell responses after pathogen encounter (139-142). Furthermore, 
Ova expressing tumour cell lines are available and a tumour challenge experiment 
was conducted in mice immunized with Stm carrying Ova epitopes.  
 
II.3.3. Displayed antigens – BRAFV600E 
The first real tumour-associated antigen included in this study was derived from the 
proto-oncogene BRAF. BRAF alleles were identified as somatic mutations in 70 % of 
melanomas and a minority of other cancers including lung, colon and ovary 
carcinomas but not normal cells (143,144) Nearly all (92 %) BRAF mutations in 
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melanoma contain a single amino acid substitution, valine on position 600 to glutamic 
acid (V600E), which is believed to mimic activating phosphorylation of serine 598/ 
threonine 601 of wildtype BRAF. This mutation leads to constitutive activation of the 
protein. BRAFV600E transforms cells in vitro through activation of the mitogen 
activated protein kinase (MAPK) pathway (143) which consists of the kinases RAS-
RAF-MEK-ERK-MAPK mediating cellular responses to growth signals (145). 
Because of its tumour specificity and expression in the majority of melanomas, 
mutated BRAF is a potentially promising target for cancer immunotherapy as it 
represents a TAA of the type II (see II.1.3). Recently, a mutation-specific, HLA-B27 
restricted epitope of BRAFV600E was discovered with spontaneous CTL responses 
in melanoma patients (146). The respective epitope was cloned in triplicate into the 
tolC loop, transferred into Stm and assessed for its capacity to elicit CD8+ responses 
in vaccinated mice transgenic for the human HLA-B27 allele.  
 
II.3.4. Displayed antigens – PSA 
The last investigated antigen in this work is represented by the prostate-specific 
antigen (PSA). PSA is a 34 kDa glycoprotein, primarily produced by the prostate 
ductal and acinar epithelium (147). Interestingly, in prostate cancer cells expression 
of PSA is markedly increased compared to normal prostatic cells (148). Furthermore, 
its expression is restricted to the prostate and not found in normal cells, rendering 
PSA a tumour-associated antigen of class III (see II.1.3). Prostate cancer is the most 
common form of cancer affecting men in the United States, and is the second leading 
cause of cancer deaths among men each year (149). Although several curative 
therapies exist for localized disease, such as radical prostatectomy, radiation 
therapy, and cryotherapy, approximately 20-40 % of treated patients will relapse 
(150,151). Since prostate cancer is dependent upon androgens for growth, treatment 
for advanced, metastatic disease is achieved by systemic androgen deprivation 
(152). Albeit initial success, androgen independent clones arise in most patients 
making the disease untreatable (153). For these reasons, immune therapy targeting 
PSA is an attractive alternative for both hormone-refractory and non-refractory 
cancers. Various approaches have been developed in this respect including DNA 
vaccines, viruses and DC-based vaccines to elicit PSA-specific immune responses 
(154-156). However, due to unknown reasons, results have been very disappointing 
when modalities were extended to clinical trials (157). Recent findings of our group 
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demonstrated that vaccination with Stm secreting PSA in combination with cholera 
toxin subunit B (CtxB) as adjuvant significantly decelerated tumour growth in a PSA 
expressing tumour xenograft model (115). This protection was correlated with CTL 
responses that were elicited emphasizing the promising perspectives for prostate 
cancer immune therapy based on LBV. Moreover, an immunodominant murine, H-
2Db restricted CTL epitope of human PSA was discovered recently (158) allowing to 
investigate PSA directed T-cell response in H-2b mice. The selected epitope contains 
two putative H-2Db binding peptides: a 9-mer, encompassing aa 65-73 and a 10-mer 
consisting of aa 65-74 of the PSA protein. In this work, a recombinant Stm strain 
expressing TolC inserted with the 10-mer PSA epitope was subject of a tumour 
challenge experiment employing a melanoma cell line expressing PSA. 
 
II.4. Objectives – part II 
II.4.1. The hemolysin secretion system in Ty21a 
A second project of the present thesis aimed at improving the hemolysin secretion 
system in Ty21a for vaccination purposes. In an earlier study, the feasibility of this 
system in Ty21a was demonstrated (159). For this initial work, full length HlyA was 
utilized as heterologous antigen and successfully expressed and secreted by Ty21a. 
Furthermore, mice immunized with secretion-competent Ty21a developed serum 
antibodies against hemolysin, demonstrating that the type I secretion system is 
functional in Ty21a and could form the basis for combination vaccines for human use 
e.g. in cancer immunotherapy. 
In order to enhance immunogenicity of this system we sought to increase secretion 
efficiency in Ty21a as the amount of free antigen is linked with immunogenicity. For 
this purpose a closer look at the regulation of type I secretion of hemolysin needs to 
be taken. As aforementioned, the secretion apparatus consist of three components, 
namely TolC/HlyB/HlyD (160) secreting the RTX toxin haemolysin (HlyA), a virulence 
factor of extra-intestinal E .coli (161). HlyC modifies pro-HlyA to its hemolytically 
active form in the cytoplasm due to its function as fatty acid acyltransferase (162). 
The tolC gene is located on the chromosome, being part of the mar-sox regulon 
(163), while the other factors are encoded on one polycistronic mRNA derived from 
the hlyCABD (164) operon located on transmissible plasmids or chromosomal 
pathogenicity islands (165,166). The operon is transcribed from a promoter located 
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upstream of hlyC in a strongly polar manner due to the presence of a rho-
independent terminator in the hlyA-hlyB intergenic region (167). This termination is 
suppressed by RfaH which interacts with a cis-acting 5’ DNA sequence termed 
operon polarity suppressor (ops) element, allowing efficient transcription of the entire 
hly operon by inhibiting transcriptional pausing (168-170). The regulatory cascade is 
schematically envisaged in Figure II.2. 
 
 
 
Figure II.2 Genetic regulation of the hemolysin operon (hlyCABD) and type I secretion of hemolysin 
(HlyA) in E. coli 
A: Transcription of hlyCABD shows strong polarity due to a terminator in the hlyA-hlyB intergenic site. 
RfaH binds to the ops element and suppresses termination leading to transcription of the full length 
polycistronic mRNA and efficient secretion like depicted in B: HlyC activates HlyA in the cytoplasm 
followed by direct secretion of mature hemolysin via the tripartite type I secretion machinery 
HlyB/HlyD/TolC into the extracellular space (ES). ops: operon polarity suppressor element, OM: outer 
membrane, IM: inner membrane 
 
In this part of the work, Ty21a was analysed for its secretion efficiency compared to 
other Salmonella strains. By analysing known Ty21a mutations and genetic 
complementation, it was tried to find factors positively regulating secretion of 
hemolysin in Ty21a and evaluate their contribution to immunogenicity in a mouse 
model by assessing serum antibody titres against hemolysin. This in turn could lead 
to the development of new generation vaccines based on this secretion system 
facilitating enhanced immunogenicity against secreted heterologous antigens.
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III. Material and Methods 
III.1. Material 
III.1.1. Bacterial strains 
 
Name Relevant characteristics  Source or reference 
E. coli DH5α F-, ø80dlacZ M15, (lacZYA-argF) U169 Invitrogen, Karlsruhe, 
  deoR, recA1, endA1, hsdR17(rk-, mk+),  Germany 
  phoA, supE44, λ-, thi-1, gyrA96, relA1 
Listeria monocytogenes trpS, balanced lethal plasmid system (171) 
EGDe ∆trpS  
Salmonella enterica serovar  aroA, fliC::Tn10 Stocker, B. A. D 
Dublin aroA SL5928   
S. enterica serovar  S. typhi Ty2, galE, rpoS, viaB Berna Biotech Ltd.,  
Typhi Ty21a (Ty21a)   Berne, Switzerland 
S. enterica serovar  S. typhi Ty2, galE, rpoS, viaB, tolC this study  
Typhi Ty21aTC 
(Ty21aTC) 
Salmonella enterica serovar  hisG46, DEL407 [aroA544::Tn10 (Tcs)] Stocker, B. A. D 
Typhimurium aroA SL7207 
(Stm)  
Salmonella enterica serovar  hisG46, DEL407 [aroA544::Tn10 (Tcs)] this study 
Typhimurium aroA  tolC 
SL7207TC (StmTC) 
 
III.1.2. Cell lines 
 
Name Relevant characteristics  Source or reference 
B16-Ova mouse melanoma cell line expressing Juergen Hess,  
 chicken ovalbumin Erlangen  
Caco-2 human colon carcinoma ATCC 
EG.7 derivative of EL-4 thymome expressing ATCC 
 chicken ovalbumine 
RAW 264.7 murine leukaemic macrophage-like cells ATCC 
P815-BRAFV600E murine lymphoblast-like mastocytoma cell C. Yone, MSZ, 
 line expressing human BRAFV600E and Würzburg 
 HLA-B2705 
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III.1.3. Animals 
 
Name Relevant characteristics  Source or reference 
C57Bl/6JO1Hsd H-2b haplotype Harlan-Winkelmann 
C57Bl/6-TG(TcraTcrB) transgenic T-cell receptor specific for  (137), obtained from  
1100Mjb (OT-I) OVA257-264  in context of H2-Kb MHC I Max Planck Centre  
 molecule for Infection Biology,  
  Berlin  
C57Bl/6-TG(TcraTcrB) transgenic T-cell receptor specific for  (138), obtained from  
425Cbn (OT-II) OVA323-339 in context of I-A2 MHCII  Dept. Virology,  
 molecule University Würzburg 
Balb/c HLA-B2705 H-2d haplotype, expressing human HLA-B Prof. Weiss, Munich 
 2705 molecule 
 
III.1.4. Plasmids 
 
Name Relevant characteristics  Source or reference
pACYC184 CmR, TetR (172) 
pANN202-812 AmpR, hlyR, C, A, B, D, derivate of pBR322 (173) 
pCP20 AmpR, CmR, TS, encoding Flp-recombinase (174) 
pKD3 AmpR, CmR, priming sites for generation of (175) 
  KO fragments 
pKD46 AmpR, TS, encoding λ-RED system for  (175) 
  homologous recombination,  
pMKhly1 KanR, derivative of pMOhly1  (115) 
pRfaH CmR, derivate of pACY184, encoding rfaH  this study 
 gene of S. typhi Ty21a  
pRpoS CmR, derivate of pACY184, encoding rpoS  this study 
 gene of S. typhimurium SL7207 
pRSC2 CmR, hlyR, C, A, B, D, derivate of pACYC184 (176) 
pSP118-PSactaOVA EryR, derivative of pUNK, encoding actA  (139)  
 signal sequence-ovalbumin fusion 
pTC derivative of pTolC, KanR deleted, encoding this study 
 tolC from E. coli 
pTC-OVA derivative of pTolC-OVA, KanR deleted,  this study 
 encoding tolC-OVA257-264  and OVA323-339  
 epitopes fusion  
ptolC AmpR, derivative of pBR322, encoding tolC  (127) 
 gene from E. coli 
pTolC KanR, derivative of pMKhly1, encoding tolC  this study 
 gene from E. coli 
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Name Relevant characteristics  Source or reference
pTolC-BRAF KanR, derivative of pTolC, encoding tolC- this study 
 3xB-RAFV600E GRFGLATEK epitope fusion 
pTolC-OVA KanR, derivative of pTolC, encoding tolC- this study 
 OVA257-264  and OVA323-339 epitopes fusion 
pTolC-PSA KanR, derivative of pTolC, encoding tolC (136) 
 PSA65-74  epitope fusion 
AmpR: Ampicillin resistant; CmR Chloramphenicol resistant; EryR: Erythromycin resistant; TetR: 
Tetracycline resistant; TS: temperature sensitive replication 
 
III.1.5. Primers 
 
Name Sequence Characteristics 
BRAF-linker1 5’CGGCGATTTTGGCCTGGCGACCGAAAAAGCGGG  linker for hybridisation of  
 CGATTTTGGCCTGGCGACCGAAAAAGCGGGCGAT  BRAF fragment 
 TTTGGCCTGGCGACCGAAAAAGGTAC3’ 
BRAF-linker2 5’CTTTTTCGGTCGCCAGGCCAAAATCGCCCGCTTT  linker for hybridisation of  
 TTCGGTCGCCAGGCCAAAATCGCCCGCTTTTTCGG  BRAF fragment 
 TCGCCAGGCCAAAATCGCCGGTAC3’ 
c1_down 5´TTTTCACCATGGGCAAATAT3´ detection of CmR cassette 
Cat RT (F) 5´ACGTTTCAGTTTGCTCATGG3´ Chloramphenicol 
  transacetylase mRNA 
Cat RT (R) 5´CCGGCCTTTATTCACATTCT3´ Chloramphenicol 
  transacetylase mRNA 
DhF 5’GCTTAATGTCCAAGATGCCTAC3’ multiplex PCR 
DhR 5’GAGCAACGCCAGTACCATCTG3’ multiplex PCR 
ectolCClaI_up 5’GGGAGAGCATCGATTAACGCCAACC3’ cloning of tolC 
ectolCSalI_down 5’GGCATCGGTCGACTCGAAATTGAAG3’ cloning of tolC 
HlyA RT (F) 5´CAGCTGCAGGTAGCTTCG3´ bicistronic hlyCA mRNA and  
  polycistronic hlyCABD mRNA 
HlyA RT (R) 5´TATGCTGATGTGGTCAGGGT3´ bicistronic hlyCA mRNA and  
  polycistronic hlyCABD mRNA 
HlyD RT (F) 5´ATTCTTACCCGCTCATCTGG3´ polycistronic hlyCABD mRNA 
HlyD RT (R) 5´GTGGCAACAATTTCCACTTG3´ polycistronic hlyCABD mRNA 
htrB_up 5’GCGAGAATACGGAGAATTG3’ detection of htrB 
htrB2_down 5’ GAGGGGAAAAATTGCAG3’ detection of htrB 
InvAF 5’CGAGCAGCCGCTTAGTATTGAG3’  multiplex PCR 
InvAR 5’CCATCAAATTAGCGGAGGCTTC3’ multiplex PCR 
k1_down 5’CAGTCATAGCCGAATAGCCT3’ detection of KanR cassette 
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Name Sequence Characteristics 
OVA-linker1 5’CTCCATTATTAACTTTGAAAAACTGGCCATTTCCC linker for hybridisation of OVA 
 AGGCGGTGCATGCGGCGCATGCGGAAATTAATGA fragment 
 AGCCGGCCGTGCCGGTAC3’ 
OVA-linker2 5’CCGGCACGGCCGGCTTCATTAATTTCCGCATGCG linker for hybridisation of OVA 
 CCGCATGCACCGCCTGGGAAATGGCCAGTTTTTCA fragment 
 AAGTTAATAATGGAGGTAC3’ 
PrtF 5’CGTTTGGGTTCCTTGGATCACG3’ multiplex PCR 
PrtR 5’CTATAATGGCGGCGGCGAGTTC3’ multiplex PCR 
rfaH_up 5’GAGGATCCACAGGAAGCTTGATGCGTTTTAG3’  cloning of rfaH 
rfaH_down 5’CCTTATGGATCCCTAATGATGATGATGATGATG  cloning of rfaH 
 AATCTTGCGAAAACCGGTG3’  
rpoS_up  5’CATCGCCTGGATCCCCGGGAACG3’ cloning of rpoS 
rpoS_down  5’GACGCAAAAAGCTTTTGATGACGCGCC3’ cloning of rpoS 
RfaH RT (F) 5´AACGTACCTTCGTCAGCGA3´ rfaH mRNA 
RfaH RT (R) 5´GTGGCGTTGATTGTAGTGGT3´ rfaH mRNA 
tolCFR_up 5’CCTCGCCACTCATTTCTCCG3’ detection of tolC deletion 
tolCFR_down 5’ CGCTTACCAGACCTACAAGGGC3’ detection of tolC deletion 
tolCKO_up 5’GCGCTAAATACTGCTTCACAACAAGGAATGCAA chromosomal deletion of tolC 
 ATGAAGAAGTGTAGGCTGGAGCTGCTTC3’ 
tolCKO_down 5’CGTTATTGCTGTTGGCGCGAGCGGCGGTCGGC chromosomal deletion of tolC  
 TGTACTGCTGCATATGAATATCCTCCTTA3’ 
tolSEQ1 5’GGATTTAACGGCTTCTACC3’ detection of tolC insertion 
tolSEQ2 5’CGGCAGCGAGAAGCTCAGG3’ detection of tolC insertion 
ViaBF 5’CACGCACCATCATTTCACCG3’ multiplex PCR 
ViaBR 5’AACAGGCTGTAGCGATTTAGG3’ multiplex PCR 
multiplex primers taken from (177), c1_down and k1_down taken from (175) 
 
III.1.6. Media 
 
Name Composition Manufacturer 
Brain Heart Infusion ready made powder, 37 g/L Difco 
(BHI) 
CY medium 12 mg/ml Yeast extract , 20 mg/ml Hy-Case,  Sigma, Applichem, Roth 
 12 mg/ml pepticase, 1.25 mg/ml sodium  
 hydrogen phosphate, 3.3 mg/ml sodium  
 chloride, 2 mg/ml glucose  
DMEM DMEM, 10 % fetal bovine serum GIBCO 
Luria Bertani (LB) ready made powder, 20 g/L Sigma 
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Name Composition Manufacturer 
RP10 RPMI1640, 10 % fetal bovine serum GIBCO 
 1x MEM non-essential amino acids ,  
 1 mM sodium pyruvate, 2 mM L-glutamine 
 50 mM β-mercaptoethanol 
 
Media for bacterial culture (LB, BHI and CY) were autoclaved for 20 min at 121°C. 
Antibiotics and other temperature sensitive supplements were added after 
autoclaving and cooling of the media. For plates, media were solidified with 1.5 % 
Agar (Difco). 
 
III.1.7. Buffers and solutions 
Name Composition Manufacturer 
Acrylamide/Bis solution ready made solution, 40 % Acrylamide/Bis Bio-Rad 
 37.5:1 (2.6 % C) 
Ampicillin stock 100 mg/ml Ampicillin (Amp) in water Sigma 
Bile salt stock 200 mg cholate/deoxycholate in LB medium Sigma 
Blocking buffer 1 % BSA in PBS Sigma, Applichem 
Carbonate buffer 7 g/L sodium hydrogen carbonate Applichem 
Chloramphenicol stock 20 mg/ml Chloramphenicol (Cm) in ethanol Sigma 
Coating buffer, pH 9.6 4.2 g/L sodium hydrogen carbonate Applichem 
 5.3 g/L di-sodium hydrogen carbonate 
Conjugate buffer 0.05 % TWEEN20®, 1 % BSA in PBS Applichem, Roth, Sigma 
Coomassie Protein ready made solution Thermo Scientific 
assay reagent 
dH2O deionized water in-house desalting  
  device from Millipore 
D-PBS ready made solution, w/o calcium and  GIBCO 
 magnesium chloride 
Erythrocyte-lysisbuffer 100 ml 50 mM Tris, pH 7.65 Applichem 
 900 ml 155 mM ammonium chloride, pH 7.2 
Erythromycin stock 50 mg/ml Erythromycin (Em) in ethanol Sigma 
G418 50 mg/ml G418 sulphate in water Sigma 
Gentamycin ready made solution, 50 mg/ml  Sigma 
 Gentamycin in water  
Kanamycin stock 25 mg/ml Kanamycin (Kan) in water Sigma 
Laemmli buffer  50 mM Tris-HCl pH 6.8, 10 % glycerol,  Sigma, Applichem, Roth 
 5 % β-mercaptoethanol, 2 % SDS, 
 0.05 % bromophenol blue 
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Name Composition Manufacturer 
Loading dye ready made solution, 10 mM Tris-HCl  Fermentas 
 (pH 7.6), 0.03 % bromophenol blue,  
 0.03 % xylene cyanol FF, 60 % glycerol,  
 60 mM EDTA 
Novobiocin stock 100 mg/ml Novobiocin (Novo) in ethanol Sigma 
PBS ready made powder, 9.55 g/L Applichem  
PBS milk 5 % non-fat dried milk powder in PBS Applichem 
PBS TWEEN 0.05 % TWEEN20® in PBS Applichem, Roth 
Pen-strep ready made solution, 10,000 U/ml penicillin G, GIBCO 
 10,000 µg/ml streptomycin in normal saline 
Ponceau S solution ready made solution, 0.1 % Ponceau S in  Sigma 
 5 % acetic acid 
SDS PAGE buffer 3 g/L Tris, 14.4 g/L glycine, 1 g/L SDS Applichem 
Tris borate EDTA buffer  ready made solution (10 x), 20 ml/L Applichem  
(TBE) 
Towbin buffer 3 g/L Tris, 14.4 g/L glycine, 20 % methanol Applichem 
Trypsin/EDTA ready made solution, 0.05 % trypsine PANTM Biotech 
 0.02 % EDTA in PBS w/o calcium and  
 magnesium 
Bis: N,N’ methylene-bis-acrylamide, EDTA ethylene diamine tetra acetic acid, PBS: phosphate 
buffered saline, Tris: tris (hydroxy methyl) aminomethane, Tris-HCl: tris base-hydrogen chloride buffer 
system, SDS: sodium dodecyl sulphate 
 
III.1.8. Antibodies and FACS multimers 
 
Name Specificity Manufacturer 
25D-1.16 OVA257-264 /H-2Kb (178) 
IgG1,κ-PE isotype control BD Pharmingen 
IgG2a,λ-FITC isotype control (anti KLH) BD Pharmingen 
IgG2a,κ-CyChromeTM isotype control BD Pharmingen 
IgG2a,κ-FITC isotype control BD Pharmingen 
BRAFP2GRFGLATEKHLA-B2705- TCR specific for BRAF P2/HLA-B2705 DakoCytomation 
Dextramer-FITC 
BRAFP3GRFGLATVKHLA-B2705- TCR specific for BRAF P3/HLA-B2705 DakoCytomation 
Dextramer-FITC 
OVASIINFEKL –H-2Kb-Tetramer-PE TCR specific for OVA257-264/H-2Kb Beckman Coulter 
α-CD4-CyChromeTM (RM4-5) murine CD4 (L3T4) BD Pharmingen 
α-CD4-FITC (GK1.5) murine CD4 (L3T4) BD Pharmingen 
α-CD8a-CyChromeTM (53-6.7) murine CD8a (Ly2) BD Pharmingen 
α-CD8a-FITC (53-6.7) murine CD8a (Ly2) BD Pharmingen 
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Name Specificity Manufacturer 
α-CD16/32 murine FCγIII/II receptor BD Pharmingen 
α-CD62L-FITC (MEL14) murine CD62 (Ly22) BD Pharmingen 
α-IFNγ (R4-6A2) murine γ-Interferon  BD Pharmingen 
α-IFNγ-biotin (XMG 1.2) murine γ-Interferon  BD Pharmingen 
α-HlyAs HlyA secretion signal (115) 
α-mouse IgG-AKP murine IgG Dianova 
α-mouse IgG+IgM-AKP murine IgG and IgM Dianova 
α-mouse IgG-FITC murine IgG BD Pharmingen 
α-rabbit IgG-HRP rabbit IgG GE Healthcare 
α-TolC TolC from gram negative bacteria (179) 
α-Vα2 TCR (20.1) murine α2 side chain of T cell receptor BD Pharmingen 
α-Vβ5.1 TCR (MR9-4)  murine Vβ5.1 side chain of T cell receptor BD Pharmingen
AKP: alkaline phosphatase; FITC: Fluorescein isothiocyanat, HRP: horseradish peroxidase, PE: 
phycoerythrin, TCR: T cell-receptor 
 
III.1.9. Chemicals 
 
All Chemicals not mentioned elsewhere were obtained from Sigma, Difco, Roth and 
Applichem. 
 
III.1.10. Enzymes and special reagents 
 
Name Manufacturer/Source 
4-Nitrophenyl phosphate disodium salt-  Sigma 
hexahydrate substrate (pNPP)  
Agarose for electrophoresis Invitrogen 
BioTherm Taq Polymerase Genecraft 
BCIP/NBT, Sigma FastTM substrate Sigma 
Bovine serum albumin (BSA) Sigma 
BRAF27R2E8 Peptide P2 (GRFGLATEK) KJ Ross-Petersen ApS 
BRAF27R2V8 Peptide P3 (GRFGLATVK) KJ Ross-Petersen ApS 
Calf intestine alkaline phosphatase (CIAP) Fermentas 
Desoxynucleotides (dNTPs) Fermentas 
DNA ladder, 1 kB Fermentas 
Lipopolysaccharide (LPS) from Salmonella typhi Ty21a Berna Biotech 
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Name Manufacturer/Source 
Pfu Polymerase, cloned Stratagene 
Phusion Taq Finnzymes 
OVA257-264 SIINFEKL peptide Dept. Microbiology, Würzburg 
Polynucleotid kinase Fermentas 
Protein ladder, BenchMark Invitrogen 
rATP Fermentas 
recombinant Interleukin-2 (IL-2) Sigma 
Restriction endonucleases Fermentas 
Streptavidin alkaline phosphatase R&D Systems 
T4-Ligase Fermentas 
 
III.1.11. Consumable material 
 
Name Manufacturer 
96-well plates Nunclon, Greiner bio-one 
96-well nitrocellulose plates; millititer HA Millipore 
Cell culture flasks; 75 cm3 and 125 cm3  Greiner bio-one 
Cell culture plates; 24 wells  Greiner bio-one 
Cell scraper Greiner bio-one 
Gene pulser cuvette; 0.1 cm electrode gap  Bio-Rad 
Cryo tubes; 1.5ml  Greiner bio-one 
Insulin syringe  Braun 
Micro tube; 1.5 ml, 2 ml  Sarstedt 
Nitrocellulose; Hybond ECL Amersham 
Parafilm  Hartenstein 
Pasteurpipettes  Hartenstein 
Petri dish; 12 cm  Greiner bio-one 
Pipette tips  Sarstaedt 
Sterile filter Millex-GS; 0.22µm Millipore 
Polypropylene tubes; 15 ml and 50 ml  Greiner bio-one 
Whatman paper 3 mm 190 g/m2  Schleicher & Schuell 
X-ray films  Amersham 
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III.1.12. Instruments 
 
Name Manufacturer 
Bacterial incubator  Heraeus Instruments 
Bacterial shaker Scientific Innova 
Bacterial shredder, Fast Prep FP120  Thermo Electron Corporation 
Cell culture incubator  Heraeus Instruments 
Cell culture microscope  Leica 
Cell counting chamber, Bürker  Marienfeld 
Clean bench  Heraeus 
Developing cassette for Western Blot Dr. Goos-suprema GmbH 
Developing machine for Western Blot Agfa 
DNA Sequencer, ABI PRISM 373  ABI 
Electrophoresis power supply  Bio-Rad 
Electrophoresis unit, MiniProtean II for SDS PAGE Bio-Rad 
Electrophoresis unit, sub-cell GT for DNA electrophoresis Bio-Rad 
Elisa reader TECAN 
ELISPOT reader Autoimmun Diagnostika GmbH 
Flow Cytometer FACSCalibur Becton Dickinson 
Freezer (-20°C)  Liebherr 
Freezer (-80°C)  Nunc Advantage 
Fridge (4-8°C)  Liebherr 
Gene pulser  Bio-Rad 
Glassware Schott 
Heating block  Liebisch 
Ice machine  Scotsman 
Mega centrifuge J-6B Beckman 
Megafuge 1.0 R:  Heraeus 
Microwave  Siemens 
Mini centrifuge, 5417R, Biofuge 15  Eppendorf; Heraeus 
pH-electrode, SenTix 61 WTW 
pH-meter, inolab 720 WTW 
Pipettes  Eppendorf 
Real Time PCR machine, Rotor Gene 2000 Corbett 
Semi-dry blotting device, Trans-Blot SD Bio-Rad 
Sonicater SonoPlus HD70 Bandelin 
Thermocycler, T-Gradient Thermoblock Biometra 
Timer  Roth 
Scale SCALTEC 
Vortex genie  Scientific Industries 
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III.1.13. Kits  
 
Name Manufacturer 
DNeasy® Mini Kit QIAGEN 
DNAfreeTM Kit Ambion 
DyNAmoTM HS SYBR® Green qPCR Kit  Finnzymes 
ECLTM Western Blotting detection Kit Amersham 
First Strand® cDNA Synthesis Kit Fermentas 
RNase-Free® DNase Kit QIAGEN 
RNeasy® Mini kit QIAGEN 
QIAquick® Gel Extraction Kit QIAGEN 
QIAquick® PCR Purification Kit QIAGEN 
QIAquick® Plasmid Mini Kit  QIAGEN 
 
III.1.14. Software 
 
Name Manufacturer 
CellQuest Pro 4 Apple 
GraphPad Prism 4 GraphPad Software, Inc 
MS Excel 2003 Microsoft 
MS Word 2003 Microsoft 
MS Power Point Microsoft 
Photoshop CS2 Adobe 
Rotor-Gene Analysis Software V4.6.70 Corbett 
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III.2. Methods 
III.2.1. Microbiology 
III.2.1.1. General culture 
For overnight (o/n) cultures, one single bacterial colony was picked from a plate and 
resuspended in 5-10 ml of BHI or LB medium containing the appropriate antibiotics 
(usually diluted 1/1000 from the stock solution) and incubated o/n with vigorous 
shaking at 30°C or 37°C. Overnight cultures usually grow to the stationary phase 
within 18 h. For logarithmic cultures, overnight cultures were diluted 1/25 to 1/200 in 
fresh medium and incubated until the desired optical density at 600 nm (OD600) was 
reached. 
 
III.2.1.2. Electrotransformation of bacterial cells 
For electrotransformation of bacteria with plasmid or linear DNA, cell suspensions 
need to be salt free to avoid current flux due to the high field pulse. Cultures with an 
OD600 of approximately 0.6-0.8 were harvested by centrifugation (3,345 × g for 30-
60 min) and washed two times with ice-cold 10 % glycerol, concentrated 100 × in 10 
% glycerol and used immediately for transformation or stored at -80°C. 1-5 µl of DNA 
was mixed with 100 µl cell suspension and DNA was introduced into the bacteria by 
electroporation using a Bio-Rad Gene Pulser at 2.5 kV, 25 µF and 200 Ohm in a 0.1-
cm electroporation cuvette. Transformed cells were dissolved in 900 µl BHI incubated 
at 37°C for 1 h and then plated on LB agar plates containing the appropriate 
antibiotic for selection of the resistance gene. 
 
III.2.1.3. Preparation of infection aliquots 
Immunization aliquots were prepared by cultivating strains overnight at 37°C in 50 
(i.v. injection) to 1000 (oral and intranasal immunization) ml BHI or LB medium 
containing appropriate antibiotics. The next day, cells were harvested by 
centrifugation in a Beckmann-Coulter centrifuge, washed in PBS and concentrated 
10 (i.v.) or 200 (oral, nasal) fold in PBS containing 10-20 % Glycerol and aliquoted in 
500-1000 µl portions. Aliquots were stored at least 24 hours at -80°C before the 
bacterial titre was determined. The number of colony forming units (CFU) was 
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obtained by plating serial dilutions on BHI or LB agar plates and incubation at 37°C 
until bacterial colonies were visible. Plates containing between 30 and 300 colonies 
were counted to determine the CFU. The vials were thawed on ice 30 min prior to 
use. 
 
III.2.1.4. On-plate hemolysin assay 
Plates containing blood erythrocytes were prepared as follows: Erythrocytes were 
collected by centrifugation of 30 ml of sheep blood at 300 × g. Cells were washed 3-4 
times with 0.9 % NaCl solution until the supernatant was clear. Finally, 25 ml of the 
erythrocyte suspension was mixed with 1 L of warm LB agar to prepare blood agar 
plates. For determination of the hemolysin secretion ability, single colonies of 
assayed strains were picked, resuspended in 20 µl of sterile water. 1 µl portions of 
these solutions were spotted on LB blood agar plate and incubated for 24 h at 37°C. 
Secretion-competent colonies can be identified by a corona of lysed erythrocytes. 
 
III.2.1.5. Oxidative stress test 
For the oxidative stress test, bacterial strains were incubated in CY-medium to the 
stationary phase. The cells were harvested by centrifugation, washed with 0.9 % 
NaCl and equally separated into two tubes. Bacteria were then suspended in CY 
medium with none, 3 mM or 30 mM H2O2. Survival was assessed after 20 min 
incubation at 37°C by plating 0.1 ml cell suspension on BHI-agar and o/n incubation 
at 37°C. The percentage of surviving bacteria was determined by comparing the 
numbers of colony forming units (CFU) of H2O2 treated and untreated cells. 
 
III.2.1.6. Determination of the MIC of antimicrobial compounds 
The MIC (minimal inhibitory concentration) is defined as the lowest concentration of 
an antimicrobial agent which is sufficient to inhibit growth of a given bacterial culture. 
For determination of the MIC value 100 µl of LB was applied to a 96-well plate and a 
gradient of the assayed agent was established by twofold dilution steps of an initial 
concentration of this compound over the plate. Mid-logarithmic bacterial cultures 
were diluted to a concentration of 200 cells per µl and 100 µl of this suspension was 
applied in each well of one row per strain. The plate was incubated for 24 h at 37°C 
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and then read-out in an ELISA reader at 620 nm. Cultures with OD620 values below 
0.06 were determined as growth repressed. 
 
III.2.1.7. Determination of plasmid stability in vitro 
To investigate if plasmids are stably replicated without antibiotic selection a plasmid 
stability tests were performed in vitro. Cultures were grown in 5 ml LB to the 
logarithmic phase with selection antibiotics (AB). Afterwards, 50 µl of the culture were 
harvested in a microcentrifuge at 2,000 × g and then resuspended in either medium 
only or medium containing selection antibiotic. Both cultures were grown overnight 
with vigorous shaking at 37°C. The next day, serial dilutions of the cultures were 
plated on LB and LB agar plates and further incubated at 37°C until colonies were 
visible. Plates containing between 30 and 300 colonies were counted. The plasmid 
stability P was calculated with the following equations:  
P (%) = (CFULB AB/CFULB)raised w/o AB * 100 * FP; Def.: P ≤ 100;  
FP = (CFULB/CFULB AB)raised with AB; Def.: FP = 1 if (CFULB AB/CFULB)raised w/o AB ≥ 1 or 
(CFULB/CFULB AB)raised with AB < 1 
 
III.2.2. Molecular Biology 
III.2.2.1. PCR for cloning 
Polymerase chain reaction (PCR) is an enzymatic method for in vitro synthesis of 
multiple copies of specific sequences of DNA. For cloning purposes, high fidelity 
polymerases, namely Pfu and Phusion Taq, were used. For PCR products facilitating 
disruption of chromosomal genes according to the method of Datsenko and Wanner 
(175), BiothermTM Taq polymerase was used similar to the Pfu protocol. Typical 
protocols are shown in the following tables:  
 
1 × mix Pfu/Taq polymerase  program    
5 µl  Dimethylsulfoxid (DMSO) 10 % 95°C 5 min    
5 µl 10 × buffer Pfu/ BiothermTM Taq 1 × 95°C 1 min 
0.5 µl 100 µM primer upstream  1 µM 50°C 1 min 
0.5 µl 100 µM primer downstream  1 µM 72°C 1 min/1kb 
33x 
1 µl 10 mM dNTPs  0.2 mM 72°C 10 min 
1 µl template DNA  4°C ∞ 
} 
 
1 µl Pfu (2.5 U/µl)/Taq (5 U/µl) 2.5 U/5 U     
ad 50 µl dH20      
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1 × mix Phusion polymerase  program    
10 µl 5 × buffer Phusion 1 × 98ºC 30 s    
0.5µl 100 µM primer upstream  1 µM 98ºC 10 s 
0.5 µl 100 µM primer downstream  1 µM 60ºC 20 s 
1 µl 10 mM dNTPs  0.2 mM 72ºC 10 s /1kb 
33x 
1 µl template DNA  4ºC ∞ 
1 µl Phusion polymerase (2 U/µl) 2 U   
} 
 
ad 50 µl dH20      
 
III.2.2.2. Colony PCR 
Colony PCR was used for screening purposes facilitated by BioTherm Taq 
polymerase. With this method, single bacterial colonies or plasmids could be 
analysed for the existence of specific DNA sequences.  
 
1 × mix Taq polymerase  program    
2.5 µl 10 × buffer BioTherm Taq 1 × 95°C 5 min    
0.25 µl 100 µM primer upstream  1 µM 95°C 1 min 
0.25 µl 100 µM primer downstream  1 µM 50°C 1 min 
0.5 µl 10 mM dNTPs  0.2 mM 72°C 1 min/1kb 
30x 
1 µl template DNA/single colony  72°C 10 min 
0.3 µl Taq polymerase (5U/µl) 1.5 U 4°C ∞ 
} 
 
ad 25 µl dH20      
 
III.2.2.3. Multiplex PCR 
Multiplex PCR is used for a rapid detection and discrimination of Salmonella strains 
(in abridged form of (177)). The reaction mix was prepared as follows:  
 
1 × mix multiplex PCR  program    
5 µl 10 × buffer BioTherm Taq 1 x 95°C 5 min    
1 µl 100 µM DhF 2 µM 95°C 1 min 
1 µl 100 µM DhR 2 µM 50°C 1 min 
1 µl 100 µM InvAF 2 µM 72°C 1 min/1kb 
38x 
1 µl 100 µM InvAR 2 µM 72°C 10 min 
1 µl 100 µM PrtF 2 µM 4°C ∞ 
} 
 
1 µl 100 µM PrtR 2 µM     
1 µl 100 µM ViaBF 2 µM     
1 µl 100 µM ViaBR 2 µM     
1 µl 10 mM dNTPs  0.2 mM     
1 x single colony      
1 µl Taq polymerase (5 U/µl) 5 U     
ad 50 µl dH20      
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III.2.2.4. Direct hybridisation of DNA linkers 
For production of small-sized DNA fragments, direct hybridization of two 
complementary DNA linkers is an attractive alternative to PCR. For this purpose, 
oligos were synthesized like common PCR primers, phosphorylated and 
subsequently hybridized in a temporal temperature gradient. As the oligos contain 5’ 
overhangs that mimic restriction by KpnI endonuclease, the hybridization construct 
can be directly ligated in a vector digested with KpnI. Reactions were performed like 
listed below: 
 
phosphorylation  program    
10 µl 100 µM DNA linker 100 µM 66 µM     
1.5 µl 10 × PNK buffer B 1 x 37°C 30 min 
1.5 µl 10 mM rATP  1 mM 70°C 20 min 
0.5 µl T4 PNK (10 U/µl)  15 U   
  
ad 15 µl dH20      
 
hybridisation  program    
3.5 µl 66 µM phosphorylated linker 1 23 µM     
3.5 µl 66 µM phosphorylated linker 2 23 µM 90°C 10 min 
1 µl formamide  10 % gradient*  2 h 
 
 
ad 10 µl dH20      
 
*The temperature gradient was achieved by switching-off the heating block at 90°C and allowing it to 
cool down while leaving samples in. 
 
III.2.2.5. Gel electrophoresis 
DNA samples were mixed 1/10 with loading dye solution and subjected to 
electrophoresis in 1 % (fragments over 500 bp) or 2 % (fragments below 500 bp) 
agarose gels in an electrophoresis unit at 180 V. DNA bands were visualized under 
UV light in a gel imaging system. Agarose gels were prepared in a special gel 
chamber with 10 or 20-well combs as follows: 
 
agarose gels 
     
1 or 2 g agarose for electrophoresis 1 or 2 %     
8 µl 10 mg/ml ethidium bromide solution 4 µg/ml     
ad 200 ml TBE buffer      
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III.2.2.6. DNA purification 
All DNAs were extracted or purified using Qiagen purification kits according to 
manufacturers’ protocols. In general, DNA purification is based on selective binding 
to silica columns, washing and final elution in weak alkaline Tris-HCl buffer. 
Chromosomal DNA was extracted from bacteria with the DNeasy® Mini Kit with slight 
modifications for gram-negative species. Plasmid DNA was obtained using 
QIAquick® Plasmid Mini Kit, PCR products were purified with the QIAquick® PCR 
Purification Kit and the QIAquick® Gel Extraction Kit was used to purify DNA 
fragments after gel electrophoresis. The latter methods were carried out strictly 
following manufacturer’s protocols. 
 
III.2.2.7. DNA restriction and ligation 
DNAs were digested using restriction endonucleases from Fermentas facilitated in 
their respective buffers or according to manufacturers’ recommendations as 
suggested by the DoubleDigest® algorithm (180).  
 
In order to construct new DNA molecules the desired fragments were ligated with T4-
DNA ligase. For the ligation reaction, restricted and therefore sticky ended DNA 
fragments were mixed at a molar ratio of vector to insert 1:3-1:10, respectively. 
Ligation was performed as follows: 
 
ligation mix  program    
16 µl vector-insert mix (1:3-1:10)    
2 µl 10 × T4 ligase buffer  1 x 16°C 12 h 
2 µl T4 ligase (5 U/µl)  10 U 65°C 20 min 
  
ad 20 µl dH20      
 
III.2.2.8. Sequencing 
DNA sequencing was performed in house with an ABI PRISM 373 sequencer. 
Therefore, approx. 1 µg of DNA was mixed with 10 pmol of primer in a total volume of 
14.5 µl and subjected to sequencing according to manufacturers’ protocols.  
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III.2.2.9. RNA isolation and cDNA synthesis 
Cultures were grown in BHI medium containing the appropriate antibiotics to the early 
logarithmic (OD600 = 0.4) or stationary phase (OD600 = 2.5). 5 × 109 from the early 
and 1 × 1010 cells from the late time-point were collected by centrifugation and shock-
frozen in liquid nitrogen at -80°C for storage. Bacterial cells were lysed with a 
FastPrep shredder and total RNA was extracted with the RNAeasy Mini Kit according 
to manufacturers’ protocol. On column DNA digestion with RNase-Free DNase kit 
was performed for 20 min at room temperature. Presence of chromosomal DNA was 
analyzed by PCR with the primers htrB_up and htrB2_down. Residual DNA was 
digested with DNAfree kit, 0.5 µg of total RNA were applied for cDNA synthesis with 
random hexamers using First Strand cDNA Synthesis Kit. 
 
III.2.2.10. Semi-quantitative Real-Time PCR (qRT-PCR) 
Semi-quantitative Real-Time PCR was applied to measure the relative level of 
transcript of certain genes compared to a control strain. The primers Cat RT (F) and 
Cat RT (R) were used to amplify a 136 bp fragment specific for the cat gene. The 
primers HlyA RT (F) and HlyA RT (R) were used to amplify a 121 bp fragment 
specific for the hlyA gene. The primers HlyD RT (F) and HlyD RT (R) were used to 
amplify a 135 bp fragment specific for the hlyD gene. The primers RfaH RT (F) and 
RfaH RT (R) were used to amplify a 91 bp fragment specific for the rfaH gene. qRT-
PCR was performed on the Rotor-Gene 2000 using DyNAmo™ HS SYBR® Green 
qPCR Kit. In a total volume of 20 µl each sample was analysed in triplicate, each 
qRT-PCR was performed in duplicate. 1 µl of tenfold diluted cDNA was used for qRT-
PCR. The presence of the primer specific amplicon was determined by detection of 
one melting-temperature peak and a single band at the expected size on a 2 % 
agarose gel after electrophoresis. The Ct values were determined with the Rotor-
Gene Analysis Software V4.6.70. By raising 2 by the power of the corresponding Ct 
value a relative unit for comparison of the initial RNA amount was calculated. The 
relative changes in gene expression between different strains were calculated after 
normalization with the cat gene as internal control. Significances of regulation were 
calculated using Students T-Test. Conditions applied for qRT-PCR are listed below:  
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1 × mix qRT-PCR  program    
   95°C 15 min    
10 µl 2 × Sybr green Mastermix 1 x 94°C 10 s 
1 µl 10 µM primer upstream  1 µM 57°C 20 s 
1 µl 10 µM primer downstream  1 µM 72°C 30 s 
40x 
1 µl cDNA  72°C 5 min 
ad 20 µl dH2O  70-95°C melt curve 
} 
 
 
III.2.3. Protein analysis 
III.2.3.1. Preparation of bacterial cellular proteins 
Bacteria were grown in BHI or LB medium containing appropriate antibiotics to the 
desired growth phase. 1-20 ml of culture were harvested by centrifugation and lysed 
in an appropriate amount of Laemmli buffer, cooked for 5 min and subjected to SDS 
polyacrylamide gel electrophoresis (PAGE). This fraction was referred to as cellular 
proteins or pellet proteins, as these samples contain the whole proteome of bacterial 
cells. 
 
III.2.3.2. Preparation of bacterial supernatant proteins 
Supernatant proteins were obtained by precipitating bacterial extracellular medium. 
Cultures were raised in BHI or LB medium containing appropriate antibiotics. After 
certain time points, 20 ml culture were taken, bacterial cells were collected by 
centrifugation and discarded. The resulting supernatants were precipitated with 10 % 
trichloric acid overnight at 4°C. The next day, the precipitate was collected by 
centrifugation at 3,345 × g and 4°C for 1 h, washed with 1 ml ice-cold acetone and 
carefully resuspended in 200 µl Laemmli buffer by rinsing the walls of the 
centrifugation tube. Finally, the pH was adjusted by adding 1 µl of saturated Tris 
solution; samples were cooked for 5 min and subjected to SDS PAGE. 
 
III.2.3.3. Preparation of bacterial membrane proteins 
To investigate the abundance of proteins in bacterial membranes, a quick protocol to 
separate this fraction from the cytosol was used. Cultures were grown in 20 ml LB 
medium containing appropriate antibiotics until an OD 600 of 0.9-1.1 was reached. 
Roundabout 7.5 × 109 cells were harvested by centrifugation, washed, and 
concentrated in 1 ml of PBS. Subsequently, the cells were sonicated 6-8 times with 
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15 s pulse length at 70 % output until a clear lysate was visible. Viable cells were 
collected by centrifuging for 3 min at 2,000 × g and discarded. The obtained 
supernatant was centrifuged at 10,000 × g and 4°C for 30 min. The resulting pellet 
was lysed in 200 µl Laemmli buffer w/o β-mercaoptoethanol, half was cooked and 
half was left untreated to investigate heat-labile, multimeric proteins. The pellet 
contains the membrane fraction comprised of inner and outer membrane. 100 µl of 
the supernatant was mixed 1:1 with Laemmli, cooked and referred to as cytoplasmic 
fraction. 
 
III.2.3.4. SDS PAGE 
To separate and analyze proteins, SDS polyacrylamide electrophoresis (PAGE) was 
used. SDS binding enables proteins to be electrophoretically separated according to 
their size in a polyacrylamide gel matrix. 10-40 µl of protein samples and 10 µl 
BenchMark mass standard were loaded onto gels. Electrophoresis was performed in 
a SDS PAGE running buffer containing MiniProtean II device at 180 V until the 
bromphenol front ran out of the gel. Gels were prepared as follows: 
 
Resolving gel (10 %) 
 
Stacking gel 
5 ml 40 % acrylamide/Bis solution  1.1 ml 40 % acrylamide/Bis solution  
2.5 ml 3 M Tris pH 9.0  1.25 ml 1 M Tris pH 6.8  
100 µl 20 % SDS solution  50 µl 20 % SDS solution  
20 µl TEMED  10 µl TEMED  
200 µl 10 % APS  100 µl 10 % APS  
ad 20 ml dH2O  ad 10 ml dH2O  
 
APS: ammonium persulfate, TEMED: N, N, N’, N’-tetramethylethylenediamine  
 
III.2.3.5. Western Blot 
After electrophoresis, SDS gels were equilibrated in Towbin buffer and subsequently 
transferred onto nitrocellulose membranes using a semi dry blotting device at 25 V 
for 40-75 min depending on the target protein size. To evaluate if equal amounts of 
proteins were applied on SDS PAGE, blotted membranes were stained with Ponceau 
S solution. Then, membranes were blocked in PBS milk for 1 h and incubated with 
the primary antibody (1/1000-1/3000) in PBS milk) overnight with gentle agitation at 
4°C. The remaining gels were stained with Coomassie blue to control total protein 
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amount applied for SDS PAGE. The next day, membranes were washed 3 × with 
PBS TWEEN and incubated with secondary HRP coupled antibodies (1/1000 in PBS 
milk) for at least 1 h. After additional 3 washing steps, blots were developed with the 
ECLTM Western Blotting detection Kit. 
 
III.2.4. Eukaryotic cell culture 
III.2.4.1. General culture 
RAW 246.7 macrophages were cultured in RP10; Caco-2 cells were maintained in D-
MEM and B16-Ova cells were grown in RP10 supplemented with 2 mg/ml G418 to 
ensure expression of ovalbumin. All cell lines were kept under 5 % CO2 atmosphere 
at 37°C and subcultured when they reached 90 % confluence. Subcultures of Raw 
cells were obtained by scraping the cell layer and transferring 1/10th of the 
suspension in fresh medium. Subcultures of Caco-2 and B16-Ova cells were 
prepared as follows: cellular monolayers were washed with PBS, treated with 
Trypsin/EDTA to obtain non-adhering single cells and propagated also 1:10 in fresh 
medium. 
 
III.2.4.2. Infection experiments with RAW 264.7 and Caco-2 cells 
For infection studies of eukaryotic cells with live bacteria, 5 × 105 Raw or Caco-2 
cells were seeded in 24-well TC plates 24 h prior to infection. Bacteria were washed 
in PBS, diluted in RPMI 1640 medium (w/o FCS) and then added to the cells at a 
multiplicity of infection of 100 in triplicates. Bacterial cell counts were determined by 
measuring the OD600 and confirmed by plating serial dilutions on LB agar plates. 
Bacteria were centrifuged onto cells at 500 × g for 5 min and then incubated for 2 h at 
37°C in an atmosphere of 5 % CO2. After infection, cells were washed two times with 
PBS and then incubated in RP10 (w/o FCS) containing 100 µg of gentamicin/ml After 
2 and/or 4 h of incubation, cells were washed two times with PBS and lysed with 1 % 
Triton X-100. For enumeration of intracellular bacteria, serial dilutions were plated on 
LB agar plates. CFU were counted after 24 h incubation at 37°C. Differences of 
bacterial entry and survival inside cells were analyzed using Students T-Test. 
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III.2.4.3. Plasmid stability test in macrophages 
To test stable maintenance of plasmids within macrophages, 5 × 105 Raw cells were 
seeded 24 h prior to infection in 24-well TC plates. The next day, cells were infected 
with bacteria as described in III.2.4.2 but at an MOI of 10. After 2 h, extracellular 
bacteria were killed by incubation in RPMI containing 100 µg/ml Gentamycin for 2 h. 
Subsequently, the Gentamycin concentration was lowered to 10 µg/ml and infected 
cells were incubated for 24 in the presence of FCS before cells were lysed in 1 % 
Triton and serial dilutions were plated on LB or LB Cm plates to assess the number 
of intracellular bacteria which maintained CmR conferring plasmids.  
 
III.2.4.4. Flow cytometry (fluorescent activated cell sorting, FACS) 
Flow cytometry is a qualitative method to determine expression of protein markers in 
cell populations at the single-cell level. For this purpose, approximately 1 × 106 cells 
were collected by centrifugation at 250 × g in a microcentrifuge from in vitro culture or 
single-cell splenocyte suspensions (see also III.2.5.3). Cells were washed with PBS 
BSA and incubated with either fluorochrome-conjugated or primary antibodies (1/100-
1/600 in PBS 1 % BSA) at 4°C for 30 min. In the latter case, incubation with a 
fluorochrome-conjugated secondary antibody targeting the primary antibody is 
needed. Finally, cells were washed, eluted in 400 µl of PBS BSA and analyzed in a 
BD FacsCalibur machine. Specificity of antibody mediated fluorescence was 
controlled by staining with fluorochrome-conjugated IgG isotypes or by staining cells 
with the conjugated secondary antibody only. The abundance of a specific population 
of marker positive cells in a total population can be determined by this method. 
 
III.2.5. Immunology and in vivo methods 
III.2.5.1. General animal handling and breeding 
All animal experiments were performed according to the German “Tierschutzgesetz”. 
OT-I mice were obtained from the Max-Planck Institute for Infection Biology in Berlin 
and bred for further studies in the MSZ animal facility. Therefore, one male and three 
female mice were kept together in one cage for 3 weeks. Then, mice were separated 
and 4 weeks after birth, the offspring were separated from the mother. OT-II mice 
were kindly provided by the department of Virology in Würzburg. 
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III.2.5.2. Immunization of mice with bacteria 
Three methods for immunizing mice were applied in this work. For oral immunization, 
mice were given 50 µl of carbonate buffer intragastrically 5 min prior to immunization 
to lower the pH of the stomach. Then, bacteria from infection aliquots (see III.2.1.3) 
were applied in 100-150 µl liquid by the same route. For i.v. injection, immunization 
aliquots were thawed on ice and diluted to 2.5 × 106 bacteria per ml. Mice were put 
under infrared light prior to application and 200 µl of the cell suspension were 
injected into the lateral tail vein. Immunization with Ty21a was carried out 
intranasally. Therefore, bacteria in 10-15 µl from the infection aliquots were applied 
into the nares of mice without anaesthesia using a micropipette. 
 
III.2.5.3. Isolation of murine splenocytes 
To isolate and analyze splenocytes, mice were anesthetized under CO2 atmosphere 
and killed via cervical dislocation. Spleens were removed aseptically, transferred into 
sterile D-PBS and mashed with a steel sieve to obtain a crude cell suspension. The 
suspension was centrifuged at 300 × g and 4°C; the pellet was resuspended in 3 ml 
Erythrocyte-lysisbuffer and incubated for 5 min until erythrocytes were lysed. The 
lysis buffer was neutralized by adding 10 ml of PBS and the suspension was applied 
onto a 40 µm nylon filter to give a single cell suspension. For adoptive transfer, 
splenocytes were washed and finally collected in D-PBS. For FACS analysis cells 
were washed and resuspended in PBS 1 % BSA. 
 
III.2.5.4. Determination of bacterial counts in organs and plasmid stability in vivo 
To determine bacterial counts in organs after infection, spleens or livers were 
removed and single cell suspensions were prepared like described in III.2.5.3 and 
lysed in 0.02 % TWEEN. Serial dilutions of lysates were plated on LB or LB Kan 
plates to determine plasmid stability. Stability (in %) was calculated by dividing CFU 
numbers grown on LB Kan by CFU numbers grown on LB multiplied with 100. To 
obtain plating efficiency and as an alternative to stability test by plating, grown clones 
on LB plates were picked and transferred to Kan plates. If all colonies grew on LB 
Kan, plasmid stability was also defined as 100 %. 
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III.2.5.5. OT-I and OT-II adoptive transfer 
The adoptive transfer model was used to analyze the capacity of an immunization 
strategy to elicit the expansion of ovalbumin-specific CD4+ or CD8+ T-cells. 
Ovalbumin serves as model antigen and the adoptive transfer approach is widely 
used to investigate the CD8+ or CD4+ T-cell response mediated by bacterial 
challenge (139-142). On day 1, 3-5 OT-I or OT-II mice were sacrificed and 
splenocytes were isolated and transferred into syngenic C57Bl/6 mice by i.v injection 
into the lateral tail vein. The next day, 3 of these mice per group were immunized with 
bacteria also by i.v. injection (see III.2.5.2). Three days later, mice were sacrificed 
and splenocytes were analysed by flow cytometry (see also III.2.4.4) to follow the 
expansion of Ova specific CD8+ or CD4+ T-cells. After removal and washing, 
splenocytes were treated for 5 min with the α-CD16/32 antibody on ice to block 
unspecific binding of IgG molecules to the FCγ III/II receptor via their constant part. 
To identify CD8+ cells, splenocytes were stained 30 min with the Ova SIINFEKL 
Tetramer (1/50) followed by an additional 30 min with α-CD8a CyChrome (1/200), α-
Vα-FITC (1/600), α-Vβ-PE (1/200) and/or α-CD62-L-FITC (1/400). For detection of 
CD4 T-cells, splenocytes were stained with α-CD4 CyChrome (1/200), α-Vα2-FITC 
(1/600), α-Vβ5-PE (1/200) and/or α-CD62L-FITC (1/400). All isotypes were applied in 
the same dilution as their respective specific IgG antibody. Significances in 
expansion of T-cells were calculated with 1-way ANOVA followed by Newman-Keuls 
multiple comparison test. 
 
III.2.5.6. Isolation of murine serum 
Mice were anesthetized with carbon dioxide and whole blood was obtained by 
puncturing the left ventricle of the heart. Then, mice were killed by cervical 
dislocation. Serum was extracted by incubating the whole blood for 1 h at room 
temperature following centrifugation at 10,000 × g for 5 min to separate serum from 
the cellular part. Serum was stored at -20°C until used. 
 
III.2.5.7. Enzyme linked immunosorbent assay (ELISA) 
The titres of hemolysin or LPS antibodies present in mouse sera were determined by 
ELISA. For detection of LPS antibodies, 1 µg/ml Ty21a LPS was coated onto NUNC 
96-well MaxiSorp plates at 4°C overnight. For detection of HlyA specific antibodies, 
Chapter III  Material and Methods 
 - 47 -  
HlyA was precipitated from culture supernatants using strain Ty21a pANN202-806 
following the protocol for preparation of supernatant proteins (III.2.3.2) with slight 
modifications. Instead of Laemmli-buffer, the final pellet was resuspended in PBS 
and neutralized with saturated Tris solution. Finally, the solution was diluted 1/500 in 
coating buffer and coated overnight on 96-well plates. Plates were washed twice with 
PBS TWEEN and blocked with 1% BSA in PBS. After washing twice, three dilutions 
of mouse sera (1:33; 1:100; 1:300) in 100 µl conjugate buffer were incubated in 
duplicates for 1.5 h at 37°C. After four washing steps, AKP-coupled sheep anti 
mouse IgG or anti mouse IgG and IgM diluted 1/1,000 in 100 µl conjugate buffer was 
added. After 1 h at 37°C and two washing steps, 50 µl of pNPP substrate in buffer 
was added. The reaction was incubated at room temperature and stopped after 30 
min by 50 µl 1 M NaOH. Optical density was read at a wavelength of 405 nm in a 
microplate reader. Significant differences in absorption were analyzed through 1-way 
ANOVA followed by Newman-Keuls multiple comparison test. 
 
III.2.5.8. Enzyme linked immunospot assay (ELISPOT) 
EILISPOT was performed according to (181) for analyzing the frequency of B-
RAFV600E specific, IFNγ-secreting CD8+ T-cells after immunization. For this 
purpose, 3-4 HLA-B2705 transgenic mice per group were immunized orally 3 times 
fortnightly with 5 × 109 Stm. One week after the last immunization splenocytes were 
removed and restimulated ex-vivo to expand the specific T-cell population. Therefore, 
P815 B-RAFV600E cells were pulsed for 1 h with either 10 µg/ml peptide P2 
(GRFGLATEK), P3 (GRFGLATVK) or Ova SIINFEKL as control and irradiated at 30 
Gray to serve as target cells. 2 × 106 target cells and 1 × 107 splenocytes from 
individual mice were mixed and incubated for 5 days in RP10 supplemented with 60 
U/ml IL-2 and Pen-strep (1/100). If 4 mice were vaccinated, 2 preparations were 
pooled after restimulation. Half of the medium was changed carefully after 2.5 days. 
On day prior to analysis, 96 well nitrocellulose plates were coated with 5 µg/ml IFNγ 
capture antibody (R4) o/n at 4°C. The next day, plates were blocked with 1 % BSA 
for 2 h at 37°C and washed with sterile PBS. Freshly prepared splenocytes from 
HLA-B2705 mice were pulsed with the three peptides as described above and 
irradiated with 10 Gray to serve as feeder cells. Either 1 × 104, 3 × 104 or 1 × 105 
splenocytes were incubated with 1 × 105 feeder cells in 100 µl RP10 medium plus the 
usual supplements in each well of the prepared microtiter plates for 20 h at 37°C 
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under 5 % CO2 atmosphere. Afterwards, plates were washed 10 × with PBS following 
10 × with PBS TWEEN in a microplate washer and incubated with the secondary, 
biotinylated IFNγ detection antibody (XMG 1.2, 0.25 µg/ml in 100 µl PBS Tween) for 
2 h at 37°C. After washing 10 × with PBS TWEEN, plates were incubated with 100 
µl/well streptavidin-conjugated AKP diluted 1/2,000 in conjugate buffer for 1h at 37°C. 
Finally, plates were washed 5 × with PBS TWEEN and 50 µl of BCIP/NBT substrate 
(1 tablet dissolved in 10 ml dH2O) was applied in each well to visualize IFNγ spots. 
Plates were washed, dried, and specific spots were counted and analyzed in an AID 
ELISPOT reader. Each specific spot represents an IFNγ-secreting CD8 T-cell.  
In addition to ELISPOT, splenocytes restimulated with P2 were analyzed by flow 
cytometry. In order to follow the proliferation of specific T-cells after vaccination and 
restimulation, cells were incubated with HLA-B2705 P2 or P3 dextramers (1/25) for 
30 min. CD8+ T-cells were identified with α-CD8 CyChrome as described in III.2.5.5.  
 
III.2.5.9. Tumour challenge in mice 
To analyze the protective capacity of Salmonella based immunization against 
ovalbumin, 8-9 C57Bl/6 mice of 6-8 weeks of age per group were immunized 3 times 
with 2 week intervals with 5 × 109 bacteria. Three weeks after the third immunization, 
mice were challenged with the B16-Ova cell line by two s.c. injections of 5 × 105 cells 
into each flank of shaven abdominal skin. Mice were monitored over a period of 18 
days for tumour appearance and tumour volume was assessed by measuring the 
largest (a) and smallest (b) tumour diameter. Tumour volume (V) was calculated as 
rotation ellipsoid using the following formula: V = π/6 * a * b2; a > b 
The results’ significances were analyzed by Students T-Test and 1-way ANOVA 
followed by Newman-Keuls multiple comparison test. For analysis of the protective 
capacity of salmonellae presenting the PSA epitope, 8-9 C57/Bl6 mice of 6-8 weeks 
of age per group were immunized 3 times weekly with 1 × 1010 bacteria as described 
above. Two weeks after the third immunization, mice were challenged with B16-PSA 
by two s.c. injections of 5 × 105 cells into each flank of shaven abdominal skin. Mice 
were monitored over a period of 21 days for tumour appearance and tumour volume 
was assessed and analysed as described above. Significant differences in tumour 
growth were calculated with the non-parametric Mann-Whitney test as tumour 
volumes within the same groups were not distributed according to Gauss. 
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IV. Results 
IV.1. Part I: surface display of antigens via TolC 
IV.1.1. Construction of Salmonella strains expressing antigens in 
surface-exposed fashion 
IV.1.1.1. Construction of the pTolC plasmid and derivatives 
 
 
 
 
Figure IV.1 Cloning strategy for pTolC vectors 
A: Construction of pTolC. The PCR fragment of tolC included the indicated restriction sites. Vector and 
fragment were digested with SalI and ClaI and the 1.7 insert was ligated into the 4.4 kB backbone of 
pMKhly1 containing the Kanamycin resistance (KanR) and the origin of replication (ori). 
B: Construction of vectors expressing antigen-fused TolC proteins. Antigens were obtained by 
hybridizing two polylinkers carrying 5’ overhangs mimicking KpnI restriction. These fragments were 
inserted into a single KpnI restriction site of tolC on pTolC. In the upper panel, peptide sequences of 
the three investigated antigens are given. Construction of pTolC-PSA encoding the TolC-PSA protein 
is described elsewhere (136). Ova: chicken ovalbumin derived epitopes: CD8+ epitope (black) and 
CD4 + epitope (blue) separated with linker alanines (red). BRAFV600E: CD8+ epitope of BRAFV600E 
in triplicate separated by linker alanines (red). PSA: CD8+ epitope of prostate specific antigen in 
duplicate separated by linker alanines (red). 
 
To display epitopes on the surface of Salmonella vaccine strains, plasmid pTolC, 
encoding tolC from E. coli, was constructed. It formed the basis for later antigen 
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insertion into a single KpnI restriction site within a permissive, surface exposed TolC 
loop to achieve the so called “surface display” of antigens. Ampicillin resistance is 
inadequate for possible human use of these vectors. Kanamycin resistance as 
selection marker was chosen because of higher acceptance and lower risk to the 
environment (182). The cloning strategy is depicted in Figure II.1. For plasmid 
construction, tolC was amplified from ptolC with primers ectolClaI_up and 
tolCSalI_down with Pfu polymerase. The resulting 1.7 kB fragment was cut with ClaI 
and SalI and ligated into the 4.4 kB backbone pMKhly1 obtained by restriction with 
the same enzymes. The ligation mix was transformed into electrocompetent E. coli 
which were plated on LB Kanamycin plates. Clones were screened for insertion by 
colony PCR with primers TolSEQ2 and k1_down. To verify tolC insertion, plasmids of 
PCR-positive clones were isolated and digested with ClaI and SalI (Figure IV.2). 
 
 
 
 
Figure IV.2 Agarose DNA gel colony PCR screen and plasmid digestion of pTolC isolates 
Left panel: Colonies grown after ligation and transformation were screened by PCR with primers 
TolSEQ2 and k1_down to obtain a 1.8 kb fragment indicating insertion of tolC.  
Right panel: pTolC plasmid isolates were digested with ClaI and SalI to visualize the tolC insert of 1.7 
kB size. M: marker  
 
For construction of epitope-bearing pTolC, the vector was cut with KpnI and 
dephosphorylized with CIAP. The insertion fragments were generated by hybridizing 
two complementary linkers (OVA-linker 1 and 2 or BRAF-linker 1 and 2, respectively) 
which carry 5’ overhangs mimicking KpnI digestion. Linkers were first adapted to the 
codon usage of Salmonella using the tables of the Kazusa DNA research institute 
(183). Those fragments were ligated into the prepared vector and clones were 
screened by PCR with primers tolSEQ1 and 2. The resulting plasmids were named 
pTolC-OVA, which carries the H-2Kb restricted Ova CD4+ and CD8+ epitopes, and 
pTolC-BRAF encoding the HLA-B2705 restricted B-RAFV600E epitope in triplicate 
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(Figure IV.1). As tolC is distributed almost ubiquitously in gram-negative bacteria, 
expression of these plasmids might result in a binding competition of chromosomal 
encoded TolC and plasmid-borne, recombinant TolC in the outer membrane of the 
carrier strains. Therefore, the chromosomal copy was deleted with the aim to 
maximize abundance of the recombinant isoforms at the bacterial surface. 
 
IV.1.1.2. Disruption of chromosomal tolC 
First, the two different Salmonella strains, Ty21a and Stm, were screened by 
multiplex PCR according to (177). S. typhi strains can be identified by a typical PCR 
pattern as all four primer pairs (invA, viaB, fliC-d, prt) bind and lead to amplification, 
whereas in serovar typhimurium only one specific PCR fragment (invA) is generated. 
Figure IV.3 A depicts the results of the PCR identification. Both strains showed the 
expected pattern. Chromosomal gene disruption in these strains was performed with 
the method of Datsenko and Wanner (175). An overview of this knock-out approach 
is depicted in Figure IV.3 B.  
 
 
Figure IV.3 Strain identification and overview of chromosomal disruption of bacterial genes  
A: Multiplex PCR with Ty21a and Stm, 4 primer pairs were used to detect typhi specific genes, 1 band 
(invA) is common among Salmonella strains. Ec: E. coli negative control 
B: Overview of the chromosomal deletion of tolC in Salmonella, taken from (175) 
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For disruption of tolC, Ty21a or Stm were transformed with plasmid pKD46 and 
grown in LB medium supplemented with 0.2 % L-(+)-arabinose for induction of gam, 
bet and exo, the gene products on the plasmid conferring the ability for homologous 
recombination with linear PCR products. These strains were incubated at 30°C to 
stably replicate the temperature-sensitive plasmid pKD46 until an OD600 of 0.6 was 
reached. Cells were washed and concentrated 200 × in PBS 10 % glycerol to make 
them electrocompetent. 
PCR products were amplified with Taq polymerase from pKD3 (for tolC KO in Stm) or 
pKD4 (for tolC KO in Ty21a) containing antibiotic resistance cassettes. Primers were 
composed of 5’ and 3’ overhangs homologous to the tolC locus which was the target 
of disruption and priming sites p1 and p2 which annealed to pKD plasmids. The final 
PCR products contained the 5’ homology region followed by an FRT site flanked CmR 
(pKD3) or KanR (pKD4) cassette and a homology region at the 3’ end. Knock-out 
fragments were generated from 400 µl of PCR product, purified, digested with DpnI 
for 3 h, purified again and eluted in 30 µl of EB buffer. Finally, 5 µl of PCR product 
were used to transform 100 µl electrocompetent cells mentioned above. Clones were 
selected on LB agar plates containing 0.2 % arabinose and 10 µg/ml Cm for Stm or 
25 µg/ml Kan for Ty21a at 30°C. Insertion of the PCR fragment into the tolC locus 
was controlled by colony PCR using primers c1_down (Stm) or k1_down (Ty21a) and 
tolCFR_up (Figure IV.4).  
 
 
 
 
Figure IV.4 Agarose DNA gels of colony PCRs to confirm tolC deletion in Ty21a and Stm 
Insertion of KanR and CmR cassettes into the tolC locus was confirmed with primers k1_down and 
TolCFR_up (Kan insert) or c1_down and TolCFR_up (Cm insert), respectively (lanes 2 and 5). 
Deletion of the resistance cassettes were verified with tolCFR primers (TolCFR) leaving a 500 bp scar 
sequence (lanes 4, 7). M: marker, 1: Ty21a, 2 and 3: Ty21a ∆tolC::KanR, 4: Ty21aTC, 5 and 8: Stm 
∆tolC::CmR, 6: Stm, 7: StmTC:  
Chapter IV  Results 
 - 53 -  
To eliminate the antibiotic resistance, insertion-positive clones were cultivated at 
37°C and screened for Amp sensitivity (loss of plasmid pKD46). Those clones were 
transformed with pCP20, a plasmid encoding Flp recombinase which targets the FRT 
sites for recombination. Incubation at 37°C activates the recombinase which 
mediates recombination of FRT sites resulting in CmR loss. Furthermore, pCP20 is 
eliminated as it is not stably replicated at temperatures above 30°C. Clones were 
screened for Amp and Cm sensitivity and the loss of the CmR cassette in the tolC 
locus by PCR, using primers tolCFR_up and tolCFR_down (Figure IV.4). The 
resulting tolC-deficient strains were named Ty21TC and StmTC, respectively. 
Plasmids were introduced into the strains by electroporation. 
 
IV.1.1.3. Expression and localization of recombinant TolC 
After construction of the carrier and plasmids, recombinant protein expression and 
localiztion was analyzed. Therefore, bacterial cells were disrupted and separated into 
cytoplasmic and membrane fractions. To analyze trimer formation, which indicates 
insertion of TolC into the outer membrane, half of the membrane fraction was left 
uncooked during sample preparation to ensure stability of heat-labile multimers. All 
samples were subjected to SDS PAGE and Western Blot using the α-TolC antibody 
(1/3000 in PBS milk). To control the efficacy of the fractionation process, blotted gels 
were stained with Coomassie blue and the protein pattern was analyzed.  
 
The left panel of Figure IV.5 shows the protein pattern after fractionation, SDS PAGE 
and Coomassie staining. Cytoplasmic and membrane fraction differ in their protein 
content as shown by Coomassie staining (Figure IV.5, left panel) which confirms 
proper separation of bacterial compartments by this method. When stained with the 
α-TolC antibody (Figure IV.5 and Figure IV.6), both, endogenous and recombinant 
TolC, can be detected in their monomeric form in the Ty21a and Stm strains. The 
tolC-deficient strains do not possess the chromosomal copy, so the 48 kDa band was 
lacking. Furthermore, recombinant TolC could be found in the cytoplasm as in the 
membrane fraction and built-up trimers in respective transformed Ty21a and Stm 
strains. Most strikingly, the amount of trimeric TolC was much higher in the tolC-
deficient strains and this was true for both investigated strains and both recombinant 
proteins. It is unclear whether the antibody can detect trimeric endogenous TolC as 
the overall trimer abundance in the tolC wildtype strains was low. Nevertheless, it 
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seems that there exists indeed a binding competition between TolC isoforms for a 
limited number of membranous TolC insertion sites. As a result, deletion of 
chromosomal tolC leads to saturation of the outer membrane with recombinant TolC. 
 
 
Figure IV.5 SDS PAGE and Western Blot of Ty21a strains after membrane preparation 
Membrane protein samples of 2 ml or cytoplasmic proteins of 0.2 ml culture were loaded in each lane. 
Left panel: Coomassie staining of a SDS gel after blotting. 
Middle panel: Western Blot of strains expressing TolC-OVA detected with the α-TolC antibody 
Right panel: Western Blot of strains expressing TolC-BRAF detected with the α-TolC antibody 
NC: Ty21aTC w/o plasmid, OVA: pTolC-OVA, BRAF: pTolC-BRAF, WT: Ty21a, TC: Ty21aTC 
C: cytoplasmic fraction, M: membrane fraction, M*: uncooked membrane fraction, TolC3. trimeric TolC, 
TolC1: monomeric endogenous TolC, rTolC1: monomeric recombinant TolC 
 
 
 
Figure IV.6 Western Blot of Stm strains after membrane preparation 
Membrane protein samples of 2 ml or cytoplasmic proteins of 0.2 ml culture were loaded in each lane. 
and TolC was detected with the α-TolC antibody 
OVA: pTolC-OVA, BRAF: pTolC-BRAF, TC: StmTC, WT: Stm, C: cytoplasmic fraction, M: membrane 
fraction, M*: uncooked membrane fraction, TolC3. trimeric TolC, TolC1: monomeric endogenous TolC, 
rTolC1: monomeric recombinant TolC 
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IV.1.1.4. Plasmid stability in vitro 
Plasmid stability is an important prerequisite for plasmid-based, recombinant live 
vaccines. Therefore, plasmid stability was assessed in Salmonella as described (in 
vitro, III.2.1.7). Furthermore, the KanR of plasmids pTolC and pTolC-OVA were 
eliminated by recombination and analyzed for expression and stability in StmTC. This 
strategy was followed to create antibiotic resistance-free vaccines that may be 
advantageous for later human use e.g. in Ty21a.  
The KanR of plasmid pTolC was inherited from pMKhly1 but originally is derived from 
plasmid pKD4, thus the KanR is flanked by FRT sites. Analogous to the deletion of 
resistance cassettes from the chromosome (see IV.1.1.2) this selection marker was 
removed by homologous recombination using Flp from plasmid pCP20. StmTC 
containing plasmids pTolC or pTolC-OVA were transformed with pCP20 and 
incubated at 37°C for simultaneous induction of the recombinase and loss of the 
temperature-sensitive plasmid pCP20. Clones were screened for Kan and Amp 
sensitivity to confirm deletion of KanR on pTolC plasmids and loss of pCP20. 
Retained plasmids were isolated and named pTC and pTC-OVA, respectively. Those 
“marker-free” plasmids could be selected in the presence of 2-4 µg/ml Novobiocin as 
tolC-deficient strains are highly susceptible to this compound, thus leading to 
maintenance of the only functional, plasmid-encoded tolC. 
Table IV.1 shows plasmid stability of all vectors in vitro, Figure IV.7 depicts 
expression of TolC encoded by marker-free vectors in StmTC. 
 
Plasmid Stm StmTC Ty21aTC 
pTolC 97-100% - - 
pTolC-OVA 100 % 91-100 % 100 % 
pTC - 96-100 % 86-91 % 
pTC-OVA - 94-100 % - 
 
Table IV.1 Stability of plasmid replication in 
Salmonella vaccine carriers. 
Cultures were grown o/n in the presence or 
absence of selection antibiotic. The next day serial 
dilutions were plated on LB or LB Novobiocin (2-4 
µg/ml). Plasmid stability was determined as 
described in III.2.1.7. All tests were performed at 
least 2 times; therefore a range of stability is given 
if single results differed. 
 
 
 
Figure IV.7 Western Blot of StmTC harbouring 
pTC or pTC-OVA 
Cultures were grown o/n in the presence (+) or 
absence of (-) 2 µg/ml Novobiocin. Lysates of 
0.1 ml culture were loaded in each lane and 
TolC was detected with the α-TolC antibody. 
TolC1: monomeric TolC, rTolC1: monomeric 
recombinant TolC 
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These results demonstrate that plasmids pTolC and pTolC-OVA are highly stable in 
Salmonella vaccine strains. Plasmid stability ranged from 90-100 % in vitro for KanR 
plasmids. In addition, resistance cassettes were not essential for expression and 
maintenance of plasmids as plasmids pTC and pTC-OVA were as stable as their 
parental vectors and allowed efficient expression of (recombinant) TolC in Stm. 
However, the KanR-bearing plasmids were used for further studies due to easier 
selection with Kanamycin. 
 
IV.1.2. Recombinant TolC proteins are functional 
IV.1.2.1. Investigation of major TolC functions with recombinant proteins 
TolC is a multifunctional protein, involved in type I secretion of hemolysin (160), 
multidrug resistance of Salmonella, invasion/survival of Salmonella in macrophages 
(184,185) and invasion into epithelial cells (186) To assess the capacity of the 
recombinant TolC proteins to substitute TolC functionally in tolC-deleted strains, 
resistance against antimicrobial agents, the ability for hemolysin secretion, invasion 
into Caco-2 cells and survival inside macrophage-like RAW cells were tested.  
 
IV.1.2.2. Resistance against antimicrobial agents 
AcrAB forms a tripartite efflux pump by recruiting TolC as outer membrane pore thus 
mediating resistance against a wide range of noxious, chemically non-related 
compounds (187). The ability for multidrug efflux of different Salmonella strains was 
tested by determining the MIC of bile salts.  
 
Strain Stm StmTC Ty21a Ty21aTC 
Plasmid - - pTolC 
pTolC 
OVA 
pTolC 
BRAF 
- - pTolC 
pTolC 
OVA 
pTolC 
BRAF 
MIC 
(mg/ml) 
>50 0.2 >50 >50 50 >50 0.05 >50 50 50 
 
Table IV.2 Bile salt MIC values of Salmonella strains 
Strains were cultivated 24 h in LB medium on 96-well microtiter plates containing twofold serial 
dilutions of bile salts. The MIC value represents the lowest concentration which repressed growth 
completely. 
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As Table IV.2 shows, tolC deficiency rendered the bacteria highly susceptible to the 
tested compound. All TolC isoforms were able to rescue this phenotype when 
introduced into Salmonella via plasmids. Albeit pTolC encodes tolC from E. coli it was 
fully functional in Salmonella with respect to multidrug efflux. Furthermore, insertion 
of epitopes into the outer loop did not negatively influence the efflux function 
underlining the permissive character of the antigen insertion site.  
 
IV.1.2.3. Ability for hemolysin secretion of recombinant TolC proteins 
Strains were transformed with plasmid pRSC2 which encodes the hly operon of E. 
coli and secretion was investigated employing two different methods. First, an on-
plate hemolysin assay was performed. Secreted hemolysin is diffusing into blood 
agar cells lysing erythrocytes thus resulting in corona formation around secretion-
competent cells. As visible in Figure IV.8 A, all strains lysed red blood cells 
independent of the TolC isoforms. In contrast, the tolC-deficient strain was not able to 
secrete hemolysin. In the second approach, hemolysin was precipitated from 
supernatants and analyzed by Western Blot with an α-HlyAs antibody (Figure IV.8 B)  
 
 
 
 
Figure IV.8 HyA secretion on Salmonella strains 
A On-plate hemolysin assay. Cell suspensions were dropped onto blood agar and incubated 24 h at 
37°C. Coronas indicate lysis of erythrocytes due to secreted hemolysin. NC: StmTC/pRSC2, PC: 
Stm/pRSC2, OVA: StmTC/pRSC2/ pTolC-OVA, BRAF: StmTC/pRSC2/pTolC-BRAF 
B: Western blot of precipitated supernatants of Salmonella strains 
Proteins of 2.5 ml TCA precipitated culture supernatant were applied in each lane. HlyA was detected 
with the a-HlyAs antibody. NC: StmTC/pRSC2, OVA: StmTC/pRSC2/pTolC-OVA, BRAF: 
StmTC/pRSC2/pTolC-BRAF 
 
Western Blot data confirmed the results described above. Again, all (recombinant) 
TolC proteins built-up functional secretion machineries with Hly proteins leading to 
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secretion of hemolysin. Similar results in both assays were obtained with Ty21a 
strains (not shown). 
 
IV.1.2.4. Invasion/survival in epithelial and macrophage-like cells 
In order to test the ability of recombinant Salmonella strains to invade into and 
survive inside epithelial cells, CACO-2 cells were infected with bacteria at an MOI of 
100. After uptake (2 h) and gentamicin mediated killing of extracellular bacteria (2 h), 
cells were lysed and the amount of intracellular bacteria was determined by plating 
serial dilutions of this lysates and counting CFU. The results are shown in Figure 
IV.9. Interestingly, Ty21a invaded and survived in Caco-2 cells approx. 1 log 
magnitude less efficient than Stm. Furthermore, the tolC mutant exhibited decreased 
numbers of intracellular bacteria indicating a role of tolC in the process of invasion or 
the ability to survive in Caco-2 cells. Both, TolC and TolC-OVA were able to restore 
the overall poor invasion ability of Ty21a in the tolC-deficient strain. Stm strains 
showed a similar behaviour but the yield of intracellular bacteria was much higher, 
even though the aroA mutation renders Stm replication defective when grown 
intracellularly (188). 
 
Figure IV.9 Invasion/survival of bacteria in Caco-2 cells 
2 h post infection, Caco-2 cells were lysed and plated for determination of the number of intracellular 
bacteria. 
A: Ty21a strains and B: Stm strains. Significances were calculated by logarithmic transformation of 
CFU values followed by Students T-Test comparing each strain with its respective wildtype (in white). 
* p-value < 0.05 
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When investigating survival behaviour of Salmonella in RAW macrophages 
employing an analogous experimental setting, contrary observations were made. In 
this case, intracellular yield of Ty21a was higher than for Stm strains (Figure IV.10). 
 
Figure IV.10 Invasion/survival of bacteria in RAW cells 
2 h post infection, macrophage-like cells were lysed and plated for determination of the number of 
intracellular bacteria. 
A: Ty21a strains and B: Stm strains. Significances were calculated by logarithmic transformation of 
CFU values followed by Students T-Test comparing each strain with its respective wildtype (in white). 
* p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001 
 
Again, a clear dependency on tolC for intracellular survival was observed for Ty21a. 
Complementation with TolC-OVA rescued the tolC phenotype, while TolC alone even 
increased the yield of intracellular bacteria significantly (p-value = 0.047). 
Surprisingly, tolC deletion exerted only a little but significant effect on intracellular 
numbers of Stm cells within macrophages. All S. typhimurium strains tested exhibited 
similar yields of intracellular bacteria. Howsoever, tolC deletion displayed at least no 
substantial negative effect on survival behaviour of Stm when infecting RAW cells. 
 
IV.1.3. Stm strains expressing surface-associated OVA failed to activate 
Ova specific CD4+ and CD8+ T-cells 
IV.1.3.1. OT-I transfer 
To assess the capacity of the newly constructed strains to prime the adaptive 
immune system adoptive transfer models were chosen. In a first attempt the 
expansion of CD8+ T-cells upon stimulation with Stm(TC) pTolC-OVA strains was 
investigated. Therefore, CD8+ T-cells specific for the Ova SIINFEKL peptide in the 
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context of MHCI molecules were purified from OT-I mice and transferred into 
syngenic C57Bl/6 mice. The next day, these mice were immunized with Stm 
displaying SIINFEKL via TolC or control strains. Three days later, mice were 
sacrificed and splenocytes were analysed by FACS for the expansion of OT-I cells. 
The Ova SIINFEKL Tetramer binds specifically to the OT-I T-cell receptor, the type of 
cell was confirmed with anti CD8 staining and CD62L served as activation marker as 
CD62L expression is lost in activated T-cells (CD62Lhi to CD62Llo). Figure IV.11 
illustrates the staining of splenocytes with the different markers. Figure IV.12 shows 
the results of the assay indicated by the mean percentage of OT-I cells in the 
population of splenocytes of 3 mice. 
 
 
 
Figure IV.11 FACS staining of splenocytes after immunization to determine frequencies of OVA 
specific CD8 T-cells. 
OVA SIINFEKL specific T cells (OT-I cells) were transferred into Bl/6 mice, mice were immunized, 
and T-cell frequencies was assessed by FACS.  
A: Splenocytes were stained with α-CD8a CyChrome and α-CD62L-FITC antibodies  
B: CD8a positive cells as indicated in A were gated and investigated for the presence of the OT-I 
TCR (OVA SIINFEKL Tetramer-PE) and activation state (α-CD62L-FITC). Numbers indicate the 
frequencies of cells in %. 
 
As visible, immunization did not result in substantial proliferation of OT-I cells in vivo. 
The overall frequency of these Ova SIINFEKL/MHC-I specific CD8+ cells was low. 
Figure IV.12 A depicts frequencies of non-activated T-cells after immunization. The 
background staining level was rather low as indicated by analysis of splenocytes from 
mice which did not receive OT-I cells. StmTC pTolC-OVA induced significant higher 
frequencies of OT-I cells compared to all other groups. However, the difference was 
marginal and was not reproducible in another experiment (not shown). Furthermore, 
most of the OT-I cells were not activated as the frequency of CD62Llo Tetramer 
Chapter IV  Results 
 - 61 -  
positive cells ranged often far below 0.5 % of the whole splenocyte population 
(Figure IV.12 B). Additionally, no significant differences in expansion of activated T-
cells in between the groups were observed. 
 
 
 
 
Figure IV.12 OT-I cell expansion after immunization with Stm strains. 
OVA SIINFEKL specific T cells (OT-I cells) were transferred into C57Bl/6 mice, mice were immunized, 
and T-cell expansion was assessed by FACS.  
The frequency of A: non-activated (CD62Lhi) and B: activated (CD62Llo) OT-cells is given as mean 
percentage of these cells of the whole splenocyte population (n = 3 mice). Significances were 
calculated by 1-way ANOVA followed by Newman-Keuls multiple comparison test. * p-value < 0.05, ** 
p-value < 0.01 
 
To confirm that Salmonella were able to colonize lymphatic tissue and to rule out that 
the inability to induce proliferation of T-cells was due to defects in infection ability or 
loss of antigen expression, CFU in livers of infected mice and plasmid stability were 
determined. Therefore, livers in parallel to analyzed spleens were extracted, 
homogenised and plated on LB and LB Kan plates. CFU was counted after 24 h of 
incubation at 37°C and plasmid stability was assessed. If plasmid stability was below 
100 %, 200 clones grown on LB agar w/o selection were streaked out on LB Kan 
plates. The next day, clones containing plasmids were assessed by the ability to 
grow in the presence of Kanamycin. This was performed to investigate the plating 
efficiency as clones that did not grow in the presence of Kanamycin may still harbour 
plasmids but did not express the resistance gene initially. 
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Table IV.3 summarizes the results of these control experiments. As visible, the yield 
of bacteria in the liver was similar in different strains, except StmTC pTolC-OVA 
which colonized this organ approx. 2-fold better than the other strains. Nevertheless, 
this difference was not significant (p-value = 0.156 compared to StmTC pTolC) and 
may also be attributed to a higher inoculation titre. Furthermore, plasmid stability 
proved to be very high in this setting, even when bacteria were passaged in vivo 
followed by 24 h incubation on LB agar plates, no colony lost the plasmid in strain 
StmTC pTolC-OVA. To sum up, poor efficacy of stimulating proliferation and 
activation CD8+ T-cells by Stm strains was neither due to loss of antigen nor poor 
capacity to colonize secondary lymphatic organs within 3 days in the murine host. 
 
Strain CFU/liver Plasmid stability Plasmid stability*
Stm pTolC 1.34 × 105 ± 8.54 × 104 100 % - 
Stm pTolC-OVA 1.47 × 105 ± 3.14 × 104 82 % - 
StmTC pTolC 9.8 × 105 ± 2.78 × 104 100 % - 
StmTC pTolC-OVA 2.62 × 105 ± 7.6 × 104 72 % 100 % 
 
Table IV.3 Colonization of the liver and plasmid stability of Stm strains used in the OT-I transfer 
Mice were immunized with 5 × 105 Stm strains, 3 days later mice were sacrificed, spleens and livers 
were removed and homogenised. Splenocytes were analysed as described above, serial dilutions of 
livers were plated on LB or LB Kan agar to determine CFU and plasmid stability. CFU values are 
indicated as means plus/minus standard deviation, differences were not statistically significant. 
Plasmid stability: assessed by plating; Plasmid stability*: assessed by streaking clones on LB Kan 
plates after 3 days passage in mice and 24 h incubation on LB agar. 
 
IV.1.3.2. OT-II transfer 
Analogous to the OT-I approach, CD4+ T-cells specific for OVA323-339 can be 
adoptively transferred into syngenic mice. The schedule was kept identical to the OT-
I approach with exception of the positive control Listeria monocytogenes EGDe ∆trpS 
(Lm) harbouring plasmid pSP118-OVA. This strain was found to induce the 
expansion of OT-I and OT-II cells in an adoptive transfer setting (139). Specific CD4+ 
T-cells were identified by the presence of CD4 and the OT-II T-cell receptor, 
indicated by binding of α-Vα2 and α-Vβ5 antibodies. Again, activated T-cells were 
discriminated from non-activated by loss of CD62L expression. As a result, no Stm 
strain was able to increase frequency of neither activated nor non-activated T-cells 
compared to controls, in contrast to Listeria monocytogenes pSP118-OVA (Figure 
IV.13). Of note, the frequencies of activated OT-II cells (Figure IV.13 B) seemed to be 
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higher than of non-activated (Figure IV.13 A) OT-II cells. This was possibly due to the 
staining procedure, as activated cells were only stained with α-Vβ5 and α-CD4 
antibodies whereas the total cell fraction was identified additionally by Vα2 
expression. Nevertheless, Stm expressing surface bound OVA were not able to 
prime specific CD4+ T-cells and no proliferation or activation of those cells occurred 
as detectable with this system. 
 
 
Figure IV.13 OT-II cell expansion after immunization with Stm and Lm 
OVA323-339 specific T cells (OT-II cells) were transferred into Bl/6 mice, mice were immunized, and T-
cell expansion was assessed by FACS.  
The frequency of A total OT-II cells and B: activated (CD62lo) OT-II cells is given as mean percentage 
of these cells of the whole splenocyte population (n = 3 mice). Significances were calculated by 1-way 
ANOVA followed by Newman-Keuls multiple comparison test. *** p-value < 0.001 as compared to all 
other groups 
 
IV.1.4. Stm strains expressing surface associated B-RAFV600E epitope 
failed to induce BRAF specific CD8+ T-cell response 
IV.1.4.1. IFNγ ELISPOT 
To determine specific immune responses mediated by vaccination of mice with 
salmonellae expressing the BRAFV600E epitope on the bacterial surface, an 
ELISPOT assay was applied. Briefly, 3-4 mice/group were immunized 3 times 
fortnightly with 5 × 109 Stm. One week after the last immunization splenocytes were 
removed and restimulated ex-vivo for 5 days in the presence of IL-2 and target cells 
pulsed with different peptides to expand specific T-cell populations. P2 and P3 
comprised B-RAF derived epitopes which were modified for stricter binding to HLA-
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B27 (D2R exchange) whereas P2 contains the V600E mutation and P3 represents 
the non-mutated wildtype peptide. In addition, an unrelated peptide, namely Ova 
SIINFEKL (P0), was included in the study to serve as negative control. After 
restimulation, cells were co-incubated with feeder cells pulsed with the described 
peptides on ELISPOT plates coated with IFNγ capture antibody. Detection was 
carried out with IFNγ detection antibody in a sandwich-like approach and a final 
phosphatase reaction. Each spot represented one IFNγ secreting T-cell stimulated by 
peptide-HLA complex recognition. The resulting plates were read-out in an AID 
ELISPOT reader device and analysed with the corresponding software. As illustrated 
in Figure IV.14, vaccination with Stm strains expressing the B-RafV600E epitope did 
not result in substantial activation or proliferation of specific T-cells since spot counts 
did not increase when restimulated cells of vaccinated mice were analysed compared 
to controls.  
 
 
Figure IV.14 IFNγ ELISPOT for detection of B-RAF specific CD8 T-cells after immunisation of HLA-
B27 transgenic mice with Stm 
HLA-B2705 transgenic mice were immunized fortnightly with 5 × 109 Stm. One week after the last 
immunization mice were sacrificed and splenocytes were restimulated ex-vivo with B-RAF derived 
peptides and controls. P0 = Ova SIINFEKL, P2 = mutated B-RAF and P3 = wildtype vBRAF. 
ELISPOT was performed by detecting cells secreting IFNγ in response to stimulation by feeder cells 
presenting different peptides in the context of HLA/MHC-class I molecules. Spot counts were 
analysed by 1-way ANOVA to evaluate significance of differences between immunization groups. 
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FNγ cell counts derived from naïve mice were rather high. However this was due to 
the effector/target cell ratio selected for the final analysis, which leads to the 
conclusion that IFNγ-positive cell counts were very low in the immunization groups. 
Furthermore, no significant difference in numbers of IFNγ-secreting T-cells was 
observed when stimulated with different peptides. For a positive result spot counts of 
T-cells stimulated with peptide P2, which contains the V600E mutation, should have 
had increased, as the HLA-B2705 molecule should be able to present the epitope on 
the surface of professional APCs. Taken together, immunization with Stm strains 
failed to induce detectable levels of P2 specific T-cells. 
 
IV.1.4.2. FACS analysis with B-RAF specific dextramers 
To confirm the ELISPOT data, frequencies of P2 and P3 directed CD8+ cells were 
determined by FACS in different splenocyte fractions restimulated with P2. Therefore, 
cells were stained with α-CD8-CyChrome and dextramers of peptides P2 and P3, 
respectively. The frequencies of double positive cells are depicted in Figure IV.15 
indicated as CD8+ T-cells with a TCR specific for peptide P2 (GRFGLATEK, assigned 
D-P2+CD8+) or peptide P3 (GRFGLATVK, assigned D-P3+CD8+) in the context of 
HLA-B2705.  
The overall frequencies of dextramer-positive CD8+ T-cells were low, meaning that 
specific T-cells did not expand extensively after restimulation. In addtion, no 
differences in numbers of specific T-cells were observed when comparing the 
individual immunization groups, which is consent with the ELISPOT data. However, 
frequencies of D-P2 positive are higher than D-P3 positive CD8+ T-cells in these 
populations of P2 restimulated cells. This difference was significant in two 
immunization groups albeit these observations could not be attributed to B-RAF 
mediated immunization as StmTC pTolC-BRAF failed to induce a significant shift 
towards D-P2+ CD8+ T-cells. Taken together, in these experimental settings 
Salmonella-based antigen presentation within surface exposed TolC loops was not 
able to mediate detectable expansion and activation of antigen specific CD4+ or 
CD8+ T-cells in vivo. This was valid for ovalbumin and B-Raf derived epitopes. 
Nevertheless, T-cell responses induced by Salmonella-based immunization might 
ranged under the detection limits of the diverse assays but may be sufficient to 
protect from challenge with antigen expressing tumours. To address this possibility, 
two xenograft models were established as described in the following. 
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Figure IV.15 FACS analysis for detection of B-RAF specific CD8 T-cells after immunisation of HLA-
B27 transgenic mice with Stm 
HLA-B2705 transgenic mice were immunized fortnightly with 5 × 109 Stm. One week after the last 
immunization mice were sacrificed and splenocytes were restimulated ex-vivo with B-RAF derived 
mutated peptide P2 (GRFGLATEK). T-cells specific for the different peptide/HLA-B2705 complexes 
were assessed by staining with α-CD8 antibody and dextramers P2 (D-P2) and P3 (D-P3), 
respectively. Frequencies of peptide specific T-cells were analysed by 1-way ANOVA to evaluate 
significances of differences between immunization groups. Students T-Test was performed to analyse 
differences of frequencies comparing T-cells positive for D-P2 and D-P3 within one immunization 
group. * = p-value < 0.05 
 
IV.1.5. Vaccination of mice with Salmonella expressing surface bound 
antigen was protective against PSA- but not Ova- positive 
tumour cell challenge 
IV.1.5.1. B16-Ova challenge 
To investigate the capacity of Salmonella-based immunization to protect from tumour 
challenge an ovalbumin-positive xenograft model was applied. First, ovalbumin 
expressing cells had to be identified. Two independent cell lines were investigated in 
a Western Blot setting. Surprisingly, neither in B16-Ova nor in EG.7 cells expression 
of ovalbumin was detectable (not shown). Therefore, the ability of cell lines to present 
Ova SIINFEKL peptide in the context of MHC class I molecules on the surface of 
cells was assessed. This assay displays increased sensitivity and ensures already 
that those cells can be targeted by CTLs with their cognate TCR. To address this 
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issue, different cell lines were incubated with the 25D-1.16 antibody that recognizes 
Ova SIINFEKL bound to MHC-I. Detection was carried out by FACS analysis after 
staining with a FITC-labelled secondary antibody. EG.7 cells were pulsed o/n with 25 
µg/ml Ova SIINFEKL peptide to serve as positive control. Figure IV.16 shows the 
results, depicted by the shift in florescence when stained with both antibodies 
compared to staining with primary antibody alone. EG.7 cells showed a very low 
staining intensity (Figure IV.16 A) indicated by a marginal shift compared to staining 
with primary antibody alone. Additionally this shift was also present when stained with 
secondary antibody alone (not shown). As conclusion, EG.7 cells did neither show 
expression of Ova nor presentation of Ova SIINFEKL on MHC-I molecules. 
 
 
Figure IV.16 FACS analysis for Ova SIINFEKL presentation in the context of MHC-I molecules 
Cells were stained with 25D-1.16 antibody recognizing Ova SIINFEKL in the context of MHC-I 
molecules. Empty curves indicate cells stained with primary antibody only. A: EG.7 cells, B: EG.7 cells 
pulsed o/n with 25 µg/ml SIINFEKL peptide, C: B16-Ova cells 
 
To exclude that MHC-I molecules were absent, EG.7 was pulsed with SIINFEKL 
peptide and a clear shift was observed, meaning that this cell type is able to present 
exogenous SIINFEKL (Figure IV.16 B). B16-Ova cells in contrast were able to 
present endogenous Ova SIINFEKL (Figure IV.16 C). Therefore, this cell line was 
used for further tumour challenge studies. 
For the protection assay, 7 C57BL/6 mice per group were immunized 3 times 
fortnightly with 5 × 109 Stm. Three weeks after the last immunization, mice were 
challenged with B16-Ova tumours by s.c. injection of 5 × 105 cells in each flank of 
shaven abdominal skin. Tumour growth was monitored over a period of 16 days. On 
day 18 post injection all mice were sacrificed because of high tumour burden. 
Throughout the whole experiment mice immunized with OVA-presenting Stm 
possessed smaller tumours than other groups (Figure IV.17) of which StmTC pTolC-
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OVA immunized mice harboured the smallest. However, these differences were not 
significant as evaluated with 1-way ANOVA and Newman-Keuls multiple comparison 
test. Immunization therefore failed to translate into efficient deceleration of tumour 
growth in a B16-Ova tumour xenograft model. 
 
Figure IV.17 Tumour growth of B16-Ova xenografts in Salmonella-vaccinated mice 
Mice (n=7/group) were immunized 3 times fortnightly with different Salmonella strains (5 × 109 
bacteria) and challenged 3 weeks after the last immunization with 5 × 105 B16-Ova cells by s.c 
injection into each abdominal flank. The results for days 10, 12, 14 and 16 post injection are depicted 
here. Tumour sizes were obtained by measuring diameters of palpable neoplasias and calculating the 
volume for rotating ellipsoids. Tumour volumes were analysed by 1-way ANOVA followed by Newman-
Keuls multiple comparison test for significant differences. 
 
IV.1.5.2. B16-PSA challenge 
As a result of the challenge experiment with the B16-Ova cell line, group numbers 
were decreased and immunization was performed weekly due to time constraints. 
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Furthermore, the number of applied bacteria for immunization was raised to 1 × 1010 
CFU.  
 
Figure IV.18 Tumour growth of B16-PSA xenografts on Salmonella-vaccinated mice 
Mice (n=8-9/group) were immunized 3 times with one week intervals with 1 × 1010 Salmonella 
intragastrically. Two weeks after the third immunization, mice were challenged with B16-PSA by two 
s.c. injections of 1 × 105 cells into each flank of shaven abdominal skin and tumour sizes were 
measured for 21 days. Differences of tumour volumes were analyzed for significance using the non-
parametric Mann-Whitney test. *: p-value < 0.05, **: p-value < 0.01 
 
Functional characterisation of the Salmonella carrier and generation of a B16 cell line 
stably expressing PSA are described elsewhere (136). In summary, 7-9 Bl/6 mice 
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were immunized weekly with 1 × 1010 Stm and 2 weeks after the last immunization 
these mice were challenged with 5 × 105 B16-PSA cells by s.c. injection into both 
abdominal flanks. Tumour growth was monitored over a period of 21 days. 
 
Tumour volumes measured at days 15–21 are illustrated in Figure IV.18. On day 16 
and 18 one mouse of the StmTC pTolC-PSA group died. This was not due to obvious 
tumour burden, since tumour volumes were rather low in these mice. Nevertheless, 
tumour volumes in StmTC pTolC-PSA immunized mice were significantly lower than 
in the naïve control observed from day 11 on (not shown) until the experiment was 
stopped. Salmonella alone also seem to elicit growth repressive effects on tumours, 
as StmTC pTolC immunized mice suffered from lower tumour sizes than naïve ones. 
However, significances for this observation were only given on day 15 and 19. Most 
strikingly, tumour growth in PSA vaccinated mice was also decelerated significantly 
compared to the Salmonella control group from day 15 on. Therefore, immunization 
with epitope displaying salmonellae facilitated specific and unspecific immune 
stimulation, leading to protection against tumour challenge. It is noteworthy that most 
tumours in this vaccinated group stayed very small throughout the whole experiment 
proving a strong cancer suppressing effect facilitated by an epitope specific immune 
reaction. However, the nature of this specificity remains to be elucidated.  
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IV.2. Part II: Improvement of the hemolysin secretion system in 
Ty21a for vaccination purposes 
IV.2.1. The hemolysin secretion system of E. coli is less efficient in 
Ty21a than in other salmonellae 
IV.2.1.1. Analysis of hemolysin (HlyA) secretion by Western Blot 
To improve the approved strain Ty21a for antigen delivery via the hemolysin 
secretion system, different Salmonella strains were investigated for their ability to 
secrete hemolysin. For this purpose, 3 different serotypes were transformed with 
plasmid pANN202-812 encoding the hly operon, raised in BHI medium and 
supernatant and cytoplasmic proteins were prepared from stationary phase cultures 
as described in III.2.3.2. Figure IV.19 illustrates the results of this assay. As visible, 
Ty21a harbouring pANN202-812 was much less efficient in expressing (Pe fraction) 
and secreting (Sn fraction) HlyA compared to the other serotypes tested. Of course, 
Ty21a alone did neither express nor secrete HlyA.  
 
 
 
 
Figure IV.19 Identification of HlyA secretion ability of different Salmonella strains harbouring plasmid 
pANN202-812 by Western Blot.  
Cellular proteins (Pe) of 0.05 ml and supernatant (Sn) proteins of 2.5 ml logarithmic culture of 
different Salmonella strains were applied on the SDS PAGE in each lane, respectively. Detection was 
carried out with α-HlyAs antibody. SL5928: Salmonella dublin SL5928, pANN: plasmid pANN202-812 
 
IV.2.1.2. Ty21a harbours mutations possibly influencing secretion 
The vaccine strain Ty21a is an attenuated mutant of S. typhi Ty2, achieved by 
multiple mutations induced by chemical mutagenesis (78). Therefore some of the 
mutations could be responsible for the less efficient hemolysin secretion ability. In 
order to test this supposition an approach for testing the effect of single mutations in 
Ty21a on hemolysin secretion was started. It was shown earlier that the galE defect 
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of Ty21a has no influence on its poor capacity for hemolysin secretion (Meier, S.R 
and Gentschev, I.). Supplementing limiting galactose (0.001 %) to the growth 
medium can overcome galE deficiency in Ty21a with respect to LPS biogenesis 
(79,189). However, galactose addition did not alter HlyA secretion efficiency in Ty21a 
pANN202-812 (Meier, S.R. and Gentschev, I.). Another prominent mutation which 
could contribute to the observed phenotype is a nonsense mutation of rpoS mediated 
by a base insertion within the respective gene. To investigate the influence of this 
alternative sigma factor on HlyA expression and secretion, rpoS was cloned from Stm 
and subjected to analysis as stated below. 
 
IV.2.2. RpoS from Stm is functional in the rpoS negative Ty21a strain 
IV.2.2.1. Plasmid construction 
The rpoS gene was amplified from chromosomal DNA of Stm. The PCR fragment 
was generated with Pfu Polymerase with primers rpoS_up and rpoS_down and 
contained putative promoter regions of rpoS as determined by the Neural Network 
Promoter Prediction algorithm (190). The 1.9 kB fragment was ligated into vector 
pACYC184 by restriction with BamHI and HindIII. Expression of rpoS was assayed in 
the rpoS-negative S. typhi Ty21a strain by a positive catalase reaction. RpoS-positive 
clones could be detected by producing visible oxygen bubbles when treated with 
hydrogen peroxide (H2O2). The extent of bubbling indicates absence or reduction of 
catalase production in strains with differing rpoS genotypes (191). The resulting 
plasmid was termed pRpoS. 
 
IV.2.2.2. Growth characteristics of Ty21a pRpoS 
Ty21a harbouring pRpoS was analysed for its growth kinetics to rule out that 
substantial changes in the metabolism occurred by expressing rpoS from plasmid. 
Therefore, Ty21a pACYC184 and Ty21a pRpoS were inoculated in BHI medium 
containing 20 µg/ml Cm, incubated under vigorous shaking at 37°C and OD600 was 
measured every hour. The OD was plotted against time in Figure IV.20. No 
differences in growth kinetics between the two strains were observed.  
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IV.2.2.3. Oxidative stress test 
The indicated strains (Table IV.4) were grown to the mid-logarithmic growth phase, 
washed and treated with different concentrations of hydrogen peroxide or left 
untreated. Then serial dilutions were plated on agar plates and the survival rate was 
assessed as described. The data (Table IV.4) demonstrate that pRpoS is functional 
in Ty21a and that the rpoS-complemented Ty21a strain is less sensitive than Ty21a 
alone. As expected, Stm showed the best survival rate in this assay. 
 
 
Figure IV.20 Growth kinetics of Ty21a strains with 
different rpoS phenotypes 
Cultures were grown in BHI and OD600 was 
measured every hour. The experiment was 
performed at least 3 times with similar results.  
 
 
 
 
 
Table IV.4 Survival rate of bacterial cultures 
treated with H2O2.  
Cells were treated with the indicated 
concentrations of H2O2 or left untreated and 
plated on BHI agar. The survival rate was 
determined by dividing CFU of treated by CFU 
of untreated cells. 
Strain 3 mM H2O2 
30 mM 
H2O2 
Ty21a 0 % 0 % 
T21a 
pRpoS 2 % 0 % 
Stm 15 % 0 % 
 
IV.2.3. RpoS influences the hemolysin secretion efficiency in Ty21a 
IV.2.3.1. Western Blot analysis of Ty21a strains with different rpoS phenotypes 
First, Ty21a pRpoS and Ty21a harbouring pACYC184 as control were transformed 
with pANN202-812 and grown in BHI. At different time points (OD600 of 0.4, 0.7, 1.4 
and 2.3) cytoplasmic and supernatant proteins were extracted and analyzed for 
differences in secretion of HlyA (Figure IV.21 left panel). Samples taken from the 
early logarithmic (OD 0.3-0.4) and stationary (OD 2.3-3.0) growth phase were found 
to display characteristic differences in secretion of HlyA between strains and were 
therefore applied for further studies. The tolC-deficient Ty21aTC pANN202-812 strain 
(NC) was not able to secrete HlyA as the outer membrane channel of the export 
machinery is lacking. 
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Figure IV.21 depicts a Western Blot detecting HlyA in Ty21a pANN202-812 
supernatant and cellular fractions. Expression (right panel) and secretion (left and 
right panel) was enhanced in Ty21a harbouring pRpoS. This was true for the 
logarithmic (OD 0.4) and stationary phase (OD 2.5), even though rpoS represents a 
sigma factor induced at the end of bacterial growth. 
 
 
Figure IV.21 Western Blot for HlyA secretion and/or expression of Ty21a strains. 
Cultures were grown in BHI and cytoplasmic or supernatant proteins were taken at indicated densities 
(OD600). Supernatant proteins (Sn) of 2.5 ml and cellular proteins (Pe) of 0.12 ml were loaded on 
each lane, respectively. Detection was carried out with the α-HlyAS antibody. 
Left panel: supernatants of Ty21a pANN202-812 harbouring pRpoS (+) or pACYC184 (-) as control. 
NC: Ty21aTC pANN202-812 
Right panel: supernatant (Sn) and cellular (Pe) proteins of Ty21a pANN202-812 harbouring pRpoS 
(+) or pACYC184 (-) as control.  
 
IV.2.3.2. Transcriptional analysis by qRT-PCR 
One reason the above described observation could be the fact that RpoS is involved 
in the growth dependent regulation of rfaH transcription and O-antigen expression in 
S. typhi (192). RfaH also enhances elongation of Escherichia coli hlyCABD mRNA 
most likely via antitermination (193) thus, increasing the expression and secretion of 
hemolysin. Therefore, the effect of rpoS on the transcription of rfaH, hlyA and hlyD 
was analyzed using transcription of cat present on plasmids pACYC184 and pRpoS 
as internal control. Strains were grown to the early logarithmic or stationary growth 
phase, RNA was isolated and reverse transcribed into cDNA. The indicated genes 
(Figure IV.22) were nanlyzed by qRT-PCR. Change in transcription was calculated by 
comparing profiles of the pRpoS-complemented strain with the control harbouring the 
empty vector pACYC184.  
Unfortunately, results were highly variable and differed from one qRT-PCR to the 
other as illustrated in Figure IV.22. No clear tendency in transcriptional profiles of 
rfaH and hlyD was observed. Taking together the results of 6 independent 
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experiments, only hlyA transcription showed a stable 2-3-fold induction when rpoS 
was present. The nature of RpoS mediated hlyA upregulation in Ty21a is therefore 
not known and can be at least in parts distinct from antitermination via rfaH. 
 
Figure IV.22 Two independent qRT-PCR experiments of the rpoS positive Ty21a strain secreting 
hemolysin  
RNA was isolated from cultures of Ty21a pANN202-812 pACYC184 and Ty21a paNN202-812 pRpoS 
grown to the early logarithmic (OD 0.4) or stationary phase (OD 2.5) and reverse transcribed into 
cDNA. Indicated genes were analyzed by qRT-PCR. The relative changes in gene expression 
between Ty21a pANN202-812 pACYC184 and Ty21a paNN202-812 pRpoS were calculated after 
normalization with the cat gene as internal control. Significances in changes of transcription were 
calculated using Students T-Test. *: P-value < 0.05, ** : P-value < 0.01 
 
Regarding the fact that rpoS regulates the expression of numerous genes, diverse 
regulational effects might have interfered with transcription of the investigated genes. 
Therefore, the influence of sole rfaH overexpression on hly transcript and protein 
levels was studied. 
 
IV.2.4. RfaH regulates hly genes as analyzed on mRNA and protein level 
IV.2.4.1. Plasmid construction 
The rfaH gene was amplified from chromosomal DNA of Ty21a with PhusionTaq and 
primers rfaH_up and rfaH_down. The resulting 800 bp fragment was ligated into 
vector pACYC184 analogous to rpoS. The construct contained the Ty21a rfaH 
promoter and C-terminal 5 × His Tag to confirm expression with a His Tag antibody 
(not shown). Ty21a harbouring pRfaH showed similar growth kinetics than Ty21a 
alone (not shown) 
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IV.2.4.2. Western Blot analysis of Ty21a overexpressing RfaH 
Ty21a pANN202-812 complemented with pRfaH was analyzed as described for 
Ty21a harbouring pRpoS. In Western Blot assay a markedly increased expression 
and secretion of HlyA was detected when multiple copies of rfaH were present on 
plasmid pRfaH compared to the control strain. The increase was similar to that 
achieved by rpoS complementation.  
 
 
Figure IV.23 Effects of rfaH on transcription, expression and secretion of HlyA. WB (A), semi-
quantitative RT-PCR (B). 
A: Cultures of Ty21a pANN202-812 pACYC184 (RfaH) and Ty21a pANN202-812 pRfaH (RfaH+) were 
grown in BHI and cytoplasmic or supernatant proteins were taken at indicated densities (OD600). 
Supernatant proteins (Sn) of 2.5 ml and cellular proteins (Pe) of 0.12 ml were loaded on each lane, 
respectively. Detection was carried out with the α-HlyAS antibody. 
B: RNA was isolated from cultures of Ty21a pANN202-812 pACYC184 and Ty21a paNN202-812 
pRfaH grown to the early logarithmic (OD 0.4) or stationary phase (OD 2.5) and reverse transcribed 
into cDNA. Indicated genes were analyzed in a Rotor-gene qRT-PCR. The relative changes in gene 
expression between Ty21a pANN202-812 pACYC184 and Ty21a paNN202-812 pRfaH were 
calculated after normalization with the cat gene as internal control. Significances in changes of 
transcription were calculated using Students T-Test. *: P-value < 0.05, **: P-value < 0.01 
 
IV.2.4.3. qRT-PCR 
On the mRNA level, hlyA increased roundabout twofold when plasmid pRfaH was 
present in Ty21a, measurable in the early logarithmic and stationary phase (Figure 
IV.23 B). Furthermore, the hlyD mRNA level increased up to twofold in the 
logarithmic phase when compared with Ty21a alone, but this benefit was lost in the 
stationary phase. Interestingly, the level of rfaH mRNA is highly increased even in the 
early logarithmic growth phase. It was shown that transcription of rfaH in S. typhi is 
growth phase dependent with peak expression at the end of the logarithmic phase 
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(194). This tight regulation seems to be altered by introducing multiple copies of rfaH 
through pRfaH. Taken together, by complementation with both, pRpoS and pRfaH, 
twofold upregulation of hlyA mRNA was achieved. This alteration of RNA levels 
seemed to be sufficient for significant differences in the level of secreted HlyA protein 
(Figure IV.21 and Figure IV.23 A) since transcription of the hlyD gene was highly 
variable (pRpoS) or not affected in all growth phases (pRfaH). 
 
IV.2.5. RpoS and RfaH effect invasion and survival of Ty21a in RAW 
264.7 macrophages 
IV.2.5.1. Invasion and survival assay 
RpoS was described to improve survival of Salmonella in macrophages by countering 
the action of nitric oxide synthase (195) which in turn could influence antigen 
presentation and immune stimulation. Therefore, the invasion and survival behaviour 
inside Raw macrophages of different Ty21a strains was assessed. Briefly, cells were 
infected for 2 h at an MOI of 100, extracellular bacteria were killed with Gentamycin 
and 2 and 4 h post infection, and cells were lysed to determine the yield of 
intracellular bacteria by plating serial dilutions on LB agar.  
 
Figure IV.24 Invasion and intracellular survival of Ty21a strains in RAW 264.7 macrophage-like cells 
A: Ty21a pRpoS (rpoSTy21a) and B: Ty21a pRfaH (rfaHTy21a). Cells were infected at a multiplicity of 
infection of 100 and lysed after 2 and 4 h post infection (p.i.). CFU was determined by plating serial 
dilutions on LB agar plates. Relative CFU was calculated by dividing the CFU from different strains by 
the CFU from Ty21a at 2 h p.i.. Significant differences in relative CFU were calculated using Students 
T-Test. * = P-value < 0.05; ** = P-value < 0.01 
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Significant differences between the intracellular CFU of Ty21a and Ty21a pRpoS 
strains were found 2 and 4 h post infection. Plasmid pRfaH in contrast, only conferred 
a benefit during the early time-point. Four hours after infection, the number of 
intracellular bacteria was equal for Ty21a and Ty21a pRfaH. While Ty21a replicates 
intracellularly with a doubling time of 2 h, Ty21a pRfaH did not show significant 
intracellular growth (Figure IV.24 B). 
 
IV.2.5.2. Plasmid stability test 
Raw macrophages were infected for 24 h with Ty21a pRpoS and Ty21a pACYC184, 
respectively before cells were lysed and serial dilutions were plated either on LB or 
LB Cm agar. Plasmid stability was determined by dividing CFU values determined by 
counting colonies on Cm containing agar plates by CFU numbers on LB plates. 
Additionally, grown clones were tested for catalase activity by the described H2O2 
reaction. Plasmid pRpoS was stably inherited in Ty21a whereas pACYC184 was 
readily lost during passage within macrophages (Table IV.5). Furthermore, rpoS was 
still functional after cultivation in macrophages since clones were able to express 
catalase. The data demonstrate that rpoS is positively selected within macrophages.. 
 
Strain Plasmid stability catalase expression 
Ty21a pRpoS 100 % 100 % 
Ty21a pACYC184 1-4 % - 
 
Table IV.5 Plasmid stability of pACYC based vectors in Ty21a after 24 h growth in macrophages 
Raw cells were infected for 24 h with indicated Ty21a strains. Serial dilutions of lysed cells were plated 
on LB or LB Cm plates and CFU was determined. Plasmid stability was calculated by comparing CFU 
on LB Cm and LB plates. Catalase expression was determined by the emergence of visible oxygen 
bubbles after H2O2 treatment. 
 
IV.2.6. Antibody responses against hemolysin but not LPS were 
enhanced after intranasal immunization of mice with Ty21a 
strains secreting HlyA 
 
In order to test the immunological effect of rpoS and rfaH, the humoral immune 
responses against HlyA and LPS of recombinant Ty21a were assessed in vivo. For 
this purpose, four groups of C57/Bl6 mice (n = 5 per group) were immunized i.n. 
twice with Ty21a pANN202-812 pRpoS, Ty21a pANN202-812 pRfaH, Ty21a 
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pANN202-812 pACYC184, and Ty21a (control). One addtional group consisted of 
naïve mice. Induction of HlyA and LPS-specific immune responses was analyzed on 
day 49 by HlyA and LPS-specific ELISA like shown in Figure IV.25. Interestingly, 
immunization with the Ty21a pANN202-812 pRfaH strain revealed a significant 
enhancement of antibody responses against HlyA (Figure IV.25 A), but not LPS 
(Figure IV.25 B) in comparison to all other groups. Furthermore, the difference in 
HlyA-specific antibody responses between experimental groups immunized with 
Ty21a pANN202-812 pRpoS and Ty21a pANN202-812 pRfaH was also statistically 
significant (p < 0.05), as determined by 1-way ANOVA followed by Newman-Keuls 
multiple comparison test. The overall reactivity of the sera against LPS was rather 
low, only 4 of 25 mice were responding to this antigen, even though detection was 
carried out with anti IgG and IgM antibodies in this case.  
 
Figure IV.25 Antibody titres present in murine sera after immunization with Ty21a strains 
HlyA (A) and LPS-specific (B) serum antibody responses of mice immunized with Ty21a pANN202-
812 pRpoS (rpoSTy21a/pANN), Ty21a pANN202-812 pRfaH (rfaHTy21a/pANN), Ty21a/pANN202-
812 (Ty21a/pANN), Ty21a (control) and naïve mice, determined by HlyA or LPS-specific ELISA with 
anti IgG (A) and anti IgG + IgM (B) detection antibodies. Data were analyzed by 1-way-Anova followed 
by Newman-Keuls multiple comparison test. * = P-value < 0.05; ** = P-value < 0.01 
 
As a result, immunization with a strain exhibiting increased expression and secretion 
of hemolysin resulted in an increased efficacy of stimulation of humoral immune 
responses against the heterologous HlyA antigen.  
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V. Discussion 
V.1. Part I: Surface display of antigens via TolC 
 
In this project, a surface display system for antigen presentation via the outer 
membrane protein TolC was employed in two different Salmonella vaccine strains. 
The first set of experiments dealt with the construction of the carriers and 
investigation of viability. In the latter part of this project, quantities and qualities of 
immune responses were subject of investigations. Three distinct antigens were 
included in preclinical studies including epitopes of the model antigen Ova and of the 
cancer-related antigens PSA and BRAFV600E.  
 
Several strategies to present epitopes on the surface of live bacterial vaccines were 
developed and it was shown earlier that surface display of antigens is superior in 
inducing immune responses over sole cytoplasmic expression (121,122,125). As 
mentioned, TolC was the membrane anchor of choice for the described antigens. The 
chromosomal tolC copy was deleted in both, Stm and Ty21a, strains to saturate TolC 
insertion sites into the outer membrane with plasmid-encoded epitope-fused TolC. 
This was performed as the level of the immune response in animals is proportionally 
to the amount of expressed antigen in live Salmonella vaccines (196,197). TolC-
BRAF and TolC-OVA were expressed and assembled as stable trimers in Salmonella 
strains and indeed, abundance of recombinant TolC trimers was higher in the knock-
out strains (Figure IV.5 and Figure IV.6).  
It was clearly demonstrated that recombinant TolC was able to complement tolC 
deficiency in the newly constructed strains with respect to multidrug efflux and Type I 
secretion (Table IV.2 and Figure IV.8). The efficiency of HlyA secretion as 
determined by on-plate hemolysin assay was comparable in Salmonella strains 
harbouring either chromosomal-encoded, plasmid-borne E. coli TolC or plasmid-
borne, recombinant E. coli TolC (Figure IV.8). Furthermore, recombinant TolC 
isoforms were able to restore the ability for survival within macrophages and invasion 
and survival in Caco-2 cells in tolC-deficient strains (Figure IV.9 and Figure IV.10). 
This was crucial as TolC plays an important role in pathogenesis of Salmonella 
strains. The exact role of TolC in this processes is discussed, ranging from direct and 
indirect effects on adhesion and invasion, secretion of an unknown factor, to 
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conferring resistance against antimicrobial peptides and bile (134,184-186,198). 
Surprisingly, the ability of Ty21a to invade and survive in Caco-2 cells was low 
compared to Stm although the latter strain has poor intracellular replication capacity 
due to the aroA mutation (188).  
Invasion of intestinal cells strongly depends on expression of genes located on the 
Salmonella pathogenicity island I (SPI-I) including a type III secretion system (199). 
Anyway, Ty21a seems to be devoid of a functional type III secretion system (personal 
communication with H Rüssmann and G. Dietrich) and this fact may explain the low 
invasion ability into Caco-2 cells of this strain. Interestingly, a recent study showed 
that the invasion deficiency of a tolC mutant was mediated by downregulation of SPI-I 
genes in Salmonella typhimurium (186). In contrast, in this work infection of Caco-2 
cells with Ty21a was shown to be dependent on tolC (Figure IV.10) leading to the 
supposition that regulation of SPI-I is not the only function of tolC in this serotype with 
respect to invasion into and survival within epithelial cells. However, TolC may 
preferentially be crucial for intracellular survival in this setting and not for entry, since 
it participates in mediating resistance against host-derived antimicrobial peptides 
(134). The intracellular yield of Stm after infection of macrophages, in contrast to 
Caco-2, was low when compared to Ty21a. Ty21a is able to replicate inside cells 
(see also Figure IV.24) while Stm is not due to its aroA mutation, thus explaining in 
parts the observed difference. Unexpectedly, also the effect of tolC on intracellular 
survival of Stm inside RAW cells was marginal. However, more recent investigations 
in our group employing Stm and its tolC-deficient derivative StmTC could 
demonstrate the crucial role of TolC for this process. The number of intracellular 
bacteria was 30-fold reduced when tolC was absent (136) which is more congruent 
with the published data (184). 
As Salmonella typhi strains are typical human pathogens, Stm strains were applied 
for animal studies and results of these experiments are now discussed. All tested 
recombinant Stm strains were able to colonize the murine liver (Table IV.3) which is a 
target organ for Salmonella typhimurium aroA in mice (200). In secondary lymphatic 
tissues, including spleen and liver, systemic immunity develops (201) and 
colonization of these organs is crucial to prime the immune system. In the same 
setting, it was shown that pTolC plasmids were retained with an astonishing stability. 
No colony of StmTC was found after 3-days passage in the murine host and 18 h on 
LB agar plates that lost antigen-encoding vector pTolC-OVA (Table IV.3). These 
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observations strengthened the results obtained by in vitro stability tests (Table IV.1). 
Usually, plasmids stabilized via antibiotics in vitro are unstably replicated in vivo due 
to the lack of selective pressure. As many live vaccines express heterologous 
antigens via those plasmids, this instability might result in loss of expression and less 
efficient antigen presentation. This can be circumvented by insertion of the antigen 
into the chromosome of the carrier (115) or by using so-called balanced-lethal 
plasmid systems (202). The first approach has limitations as single copy expression 
may also decrease antigen presentation. The latter strategy is accompanied by 
complex genetic manipulations.  
These limitations do not concern this vaccination approach. Plasmid stability and 
expression was high in the tolC-deleted strain. The reason for this stability in vivo 
may be due to: (i) high intrinsic stability of pBR322-based plasmids (203), (ii) low 
metabolic burden by antigen insertion into TolC, (iii) low replication rate of the carrier 
in vivo (188) and (iv) selective pressure to maintain TolC for the export of e.g. bile 
salts and antimicrobial peptides. This in turn leads to sustained antigen expression 
and presentation on the bacterial surface since these antigens are inserted into a 
positively selected protein. Additionally, it was accomplished to delete the Kanamycin 
resistance from plasmid pTolC in StmTC by homologous recombination. Selection in 
vitro was facilitated in the presence of Novobiocin which is a target for TolC-AcrAB 
mediated efflux (132). Plasmid stability of this construct was up to 100 % without 
selection for 18 h in vitro (Table IV.1). Additionally, TolC encoded on these vectors 
was expressed independently from antibiotic selection (Figure IV.7). Antibiotic 
resistance free plasmids are advantageous for a possible human use as they pose 
lower risks for the environment and are of higher acceptance for approving 
institutions. 
In summary, the recombinant Stm carrier strain displayed all prerequisites for efficient 
immunotherapy leading to the second part of this project which aimed to elucidate the 
nature of the immune response against (tumour) antigens and protective capacity of 
immunization. First, the successful immunization of mice with recombinant vaccine 
displaying the PSA epitope will be discussed.  
 
Tolerance is one major problem and limitation of immunotherapy of cancer: as all 
tumour antigens are self antigens specific T-cells might exist but may be attenuated 
and therefore anergic e.g. due to the action of regulatory T-cells (204,205). In 
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general, CTL responses are directed against only a few peptide epitopes of an 
antigen and this is termed immunodominance (206,207). It was suggested that 
dominant and subdominant epitopes might help to break immunotolerance of tumour 
antigens (208,209). Other attempts to override this anergy is the circumvention of 
immune checkpoints or the ablation of regulatory T-cells (for review see (2)) which 
bear the danger of collateral damage due to detrimental autoimmune responses. A 
recently discovered immunodominant epitope of PSA (158) was included in the TolC 
surface display approach. Most strikingly, the StmTC strain expressing the TolC-PSA 
fusion was able to confer protective immunity against challenge with a PSA 
expressing melanoma cell line in mice. Tumour growth was significantly decelerated 
in comparison to controls (Figure IV.18). It is widely known that Salmonella live 
vaccines can induce the proliferation of CTLs (105,210) but stimulate also parts of 
the innate immune system (211-213) which concert in the anti tumour response 
(6,10,214).  
The latter was confirmed in our studies since Salmonella alone exerted inhibiting 
effects on B16 melanoma-driven, PSA-positive tumours. Intrinsic capacity to 
stimulate components of the innate immune system represents a major advantage of 
tumour immune therapy applying LBV. This stimulation may play a key role to 
overcome anergy of T-cells in the tumour microenvironment apart from using 
dominant and subdominant tumour-derived epitopes. However, expression of the 
immunodominant CD8+ epitope within the TolC-loop was superior in decelerating 
tumour growth, suggesting that epitope specific and non-specific mechanisms act 
synergistically to protect from tumour challenge. To conclude, one CD8+ epitope 
instead of a full length protein, inserted 2-fold into the TolC loop, was sufficient to 
promote protective effects without further need of an adjuvant besides carrier 
antigens.  
The data strongly suggest that PSA specific CTLs are at least in parts the cause for 
this protection as the CD8+ epitope was sufficient to mediate significant differences 
between tumour volumes in mice. These results become even more striking when 
considering that the B16 cell line alone is poorly immunogenic and displays strong 
immune escape mechanisms compared to other cell lines (215,216). Employing TolC 
mediated surface expression of antigens circumvents another major obstacle of 
cancer immune therapy which is cancer immune evasion (see II.1.4). We are 
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currently performing an IFNγ ELISPOT (Fensterle, J. and Hotz, C., results not 
obtained yet) to elucidate the role of PSA-specific CTLs in the observed protection.  
The presented vaccination approach was shown to be protective in an infection 
model (127) and it was now demonstrated to mediate protection in a cancer 
immunotherapy approach. Therefore, TolC-based epitope display is functional in 
vaccination against infectious and neoplastic diseases. Because of these promising 
observations and the fact that TolC is almost ubiquitously expressed in gram-
negative bacteria (128), this plasmid encoded delivery system for heterologous 
antigens can be adapted to display a multitude of different epitopes also in other live 
bacterial vaccines. One of these carriers, Salmonella enterica serovar Typhi Ty21a 
that is licensed for human use (79), was engineered the same way as described for 
Stm. TolC fusion proteins were also highly expressed and functional in a tolC-
deficient Ty21a strain (Figure IV.5 and Figure IV.9) implying that this system can be 
easily transferred to human use.  
In order to characterize the cellular basis of the adaptive response mediated by 
vaccination with Salmonella, presenting epitopes on the bacterial surface more 
generally, adoptive transfer models utilizing the model antigen ovalbumin were 
established. Unfortunately, no specific and convincing CD8+ or CD4+ T-cell 
responses were measurable. In one adoptive transfer experiment a slight but 
significant increase in specific CD8+ T-cell frequencies after immunization with an 
OVA displaying Salmonella strain was detectable. However, this was not 
reproducible and cells were not activated as analysed by CD62L abundance. In 
activated (CD62L low) Ova specific T-cells no such increase was observed (Figure 
IV.12). Additionally, in a well established in vitro presentation assay StmTC 
displaying Ova failed to activate specific CD8+ T-cells irrespective of the type of 
antigen presenting cell (DCs or macrophages) used (not shown, conducted in 
cooperation with G. Geginat, RUMMS, Mannheim).  
It was demonstrated in earlier studies that frequencies of Ova specific T-cells after 
vaccination with Ova-expressing salmonellae are low, ranging in similar dimensions 
(approx 1 %) like presented in this work (141,217). The positive signal may therefore 
been overwhelmed by the “background noise”, as non-immunized mice showed 
similar frequencies of specific activated T-cells. However even if not detectable but 
present, these cells were not protective against challenge with B16-OVA xenografts 
(Figure IV.17). Salmonella evolved a multitude of mechanisms for escaping T-cell 
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recognition explaining those low frequencies. T-cell immune evasion is achieved by 
interfering with APC functions leading to decreased MHC class I and II presentation 
of peptides (for review see (218)) or directly by inhibiting T-cells due to secretion of 
inhibiting virulence factors or downregulation of the specific TCR (219,220). 
Nevertheless, T-cell immunity after Salmonella encounter was demonstrated several 
times (see II.2.3 and (217,221-223)) and also in the context of TolC-mediated surface 
display, protective immune responses were observed most likely facilitated, at least 
in parts, by T-cells recognizing their cognate epitope (127) and (Figure IV.18). These 
findings argue against a general inability of TolC-displayed antigens to prime specific 
T-cells moving the focus of possible explanations for the weak responses more to the 
nature of the individual epitope(s). Similar to TolC-OVA, TolC-BRAF also failed to 
mediate priming of specific T-cells as determined by ELISPOT (Figure IV.14). 
 
In principle, two pathways exist that result in MHC class I presentation of antigens for 
pathogens restricted to vacuoles like Salmonella (i) the vacuolar alternative pathway 
facilitated by professional APCs (DCs and macrophages), involving vacuolar 
processing of antigens loaded on pre-existing pools of MHC I molecules (106,224) 
and (ii) cross-presentation of antigen-containing particles, e.g. apoptotic blebs of 
Salmonella-infected macrophages, mediated through bystander DCs relying on 
classical antigen processing via the endoplasmatic reticulum or the proteasome and 
loading of peptides onto nascent MHC I molecules (225-227). CD4+ T-cell priming via 
MHC class II presentation of Salmonella-derived peptides is facilitated via the 
classical vacuolar pathway for exogenous antigens. Access to these presentation 
pathways may be impeded due to individual structural features of TolC fusion 
proteins.  
In the case of TolC-OVA and TolC-BRAF, the antigen might be buried in the pore of 
its membrane anchor or display other conformational constraints rendering the 
antigen hardly accessible for degradation which is crucial for presentation via MHC 
molecules. To estimate structural features, loops of the different fusion proteins were 
analysed in silico for their hydrophobicity and tendency to build transmembrane 
regions. Comparing these factors might predict if loop structures are buried within the 
protein or membranes which could hinder accessibility for protein degradation and 
presentation by APCs. However, none of the “non-inducer” fusion proteins displayed 
significant higher hydrophobicity or tendency to build transmembrane regions within 
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their antigen-fused loop structure when compared to the “inducer” TolC-PSA (Figure 
V.1). Only the loop of TolC-LisTB shows lower tendency to form transmembrane 
segments and displays less hydrophobicity than the others. Taken together, loops of 
the “inducer” fusion proteins (TolC-PSA and TolC-LisTB) do not share common 
structural features that are distinct from the non-inducers (TolC-OVA and TolC-
BRAF). Quite the contrary, TolC-PSA, TolC-BRAF and TolC-PSA seem to be very 
similar in the investigated structural characteristics with TolC-LisTB being the “odd 
one out”, thus rendering hydrophobicity and membrane affinity of the recombinant 
TolC loop structure unlikely to be the reason for low immunogenicity. Interestingly, 
TolC-PSA and TolC-LisTB exhibit shorter loop insertion fragments. Furthermore, 
TolC-PSA harbours more linker alanines (Figure IV.1) than TolC-OVA and TolC-
BRAF. Those traits might influence immunogenicity, albeit being highly speculative. 
 
 
 
 
Figure V.1 Hydrophobicity and tendency to form transmembrane regions of loop structures derived 
from different TolC fusion proteins  
The respective loops (encompassing aa 257-279 of the non-recombinant TolC protein containing the 
fused antigen) were analysed with ExPASy ProtScale (228) utilizing algorithms for estimating 
hydrophobicity from Rose et al. (229) (upper panel) and the tendency to form transmembrane 
segments (230) (lower panel). The scales were normalized from 0 to 1. 
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More generally, to my knowledge the question why surface displayed antigens are 
superior in eliciting T-cell responses still remains open. It was speculated earlier that 
surface bound expression (i) diminishes the metabolic burden opposed by 
cytoplasmic expression (127), (ii) increases the stability and accessibility of the 
antigen as it is not packaged into inclusion bodies and therefore not degraded in the 
bacteria like cytosolic expressed antigens (231), (iii) enhances immunogenicity as 
surface-exposed antigens co-localize to LPS which possesses intrinsic adjuvant 
properties (232) and (iv) allows easier processing of antigens by the described MHC 
presentation pathways (233).  
However, the latter hypothesis has not been experimentally addressed. A possibility 
for such enhanced accessibility of outer membrane contents for processing prior to 
MHC presentation could be the occurrence of outer membrane vesicles (OMVs). 
Those vesicles are naturally discharged as discrete, closed outer membrane blebs 
from growing gram-negative bacteria (234,235). They encompass contents of the 
outer membrane and periplasm such as porins, receptors, pores and LPS, excluding 
products of the cytoplasm or inner membrane (236). OMVs are central to export and 
toxicity of different virulence factors, inter-bacterial material transfer and 
communication and play a role for pathogenicity of certain gram-negative species (for 
review see (237)). OMVs derived from Salmonella were shown to elicit protective B 
and CD4+ T-cell responses against proteins of the outer membrane and display 
strong pro-inflammatory properties due to potent stimulation of the innate immune 
system (238,239). As TolC is found in those vesicles (Gentschev, I and Mayer, R. S., 
unpublished), shedding of those structures might represent an alternative way for the 
host immune system to gain access to TolC or other membrane proteins fused to 
antigens for MHC presentation besides vacuolar degradation of the whole carrier. On 
the other hand LPS shedding is suggested to inhibit T-cell activation in vivo (240) and 
excessive budding of OMVs could result in a more immune-dampening effect due to 
their LPS content.  
Further studies in this respect may shed light into processing and superior 
presentation of outer membrane-anchored antigens. These observations pose 
possible options for elevating the T-cell stimulatory capacity. Increased shedding of 
these vesicles mediated by interfering with the tol-pal regulatory system (241) may 
form a wanted process to enhance membrane-bound antigen in the vacuolar 
compartment possibly leading to more efficient MHC class II presentation. However, 
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those mutants are fragile and enhanced shedding of OMVs correlates with virulence 
(242-244). An already established way to enhance CD8+ responses is to allow 
excess of Salmonella-derived antigens into the class I presentation compartment, the 
cytosol. Listerolysin, a pore forming protein mediates escape of Listeria 
monocytogenes into the host cytosol (245). Applying this factor for export via the 
hemolysin secretion system allowed Salmonella to open the phagosome to some 
extent, providing access to the cytosolic compartment and thereby inducing potent 
CTL responses (246). Furthermore, a combination of Ova antigen and Listerolysin 
expressed in E. coli elicited potent protection from Ova-positive tumour cell challenge 
in mice compared to poor protection when immunizing with E. coli expressing Ova 
alone. This superior effect was not only achieved by changing the 
compartmentalization of the heterologous antigen but also by unexpectedly inhibiting 
CD4+ CD25+ regulatory T-cells (247) implying a very promising role for those 
modifying enzymes in cancer immune therapy. 
 
As mentioned earlier vaccination with Salmonella expressing the BRAFV600E 
epitope on its surface failed to mediate priming of specific CD8+ T-cells. Despite the 
discussed conformational constraints other observations could explain this low 
immunogenicity. Interestingly, the HLA-B27 allele and infection with pathogens like 
Salmonella are linked to reactive arthritis (248,249). It is hypothesized that HLA-B27-
restricted CTLs activated against Salmonella-derived peptides might cross-react 
through molecular mimicry with endogenous peptides presented by HLA-B27, leading 
to autoimmunity (250). Furthermore, Salmonella interfere with HLA-B27 functions by 
inducing an alternative splicing of the pre-mRNA of this allele in transfected cell lines 
(251) and by downregulation of HLA-B27 molecules in infected patients (252). These 
described alterations of HLA expression could preclude efficient class I presentation 
of the BRAF epitope following vaccination with Salmonella.  
Up to now, we were not able to observe convincing T-cell priming with Salmonella 
vaccines in this setting, earlier vaccination experiments employing secreted antigen 
delivery also failed to elicit specific CD8+ T-cell responses (Yone, C, unpublished) 
and we are currently trying to assess the role of Salmonella itself on HLA-B27 
presentation. By using DNA vaccines against mutated BRAF we want to exclude a 
general incompetence of HLA-B27 transgenic mice to present the epitope of mutated 
BRAF (Polzien, L., Hotz, C., and Fensterle, J.). In addition, colleagues are currently 
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working on the generation of BRAFV600E-positive and BRAFV600E-driven tumour 
xenograft models (Polzien, L.) as well as the generation of transgenic mice with 
BRAFV600E expression targeted to the lung (Luetkenhaus, K, Zanucco, E, Rapp, 
U.R.). These systems might be used in the future for immunization studies in tumour 
xenografts and spontaneous lung tumour settings, respectively. 
In principle, targeting of oncogenes like BRAFV600E in their function as tumour-
associated antigens poses an attractive and promising approach since it is believed 
that oncogene expression is not lost by immune evasion mechanisms due to their 
transforming and therefore indispensable character. This phenomenon was termed 
“oncogene addiction” (253). However, the BRAFV600E genotype was lost during 
transition from primary to metastatic disease in melanoma patients positive for HLA-
B27 and specific T-cells (146), thus indicating the protective role of HLA-B27 but also 
representing a major limitation due to restriction of this epitope for vaccination against 
early stage melanoma. Our further experiments will elucidate the feasibility of 
Salmonella-based vaccination against the HLA-B27 restricted epitope as therapy 
against BRAFV600E-driven cancers. 
 
V.2. Part II: Improvement of hemolysin secretion in Ty21a for 
vaccination purposes 
 
Ty21a, the active compound of Vivotif®, represents the only licensed live typhoid 
vaccine in humans (83) and due to its well studied safety (for review see (254)) it 
represents an attractive carrier for delivery of heterologous antigens. Recently, two 
clinical trials assessed Ty21a as carrier for heterologous Helicobacter pylori antigens 
expressed in the cytoplasm of this live vaccine. The vaccine was safe but showed 
low immunogenicity (86,87). As mentioned several times in this work, the fashion of 
expression of heterologous antigens within live bacterial vaccines is crucial for 
immunogenicity and secreted or surface displayed antigens are superior in eliciting 
immune responses over cytoplasm-located antigens (110,118,127,255). One of the 
promising systems for such a delivery is the use of the hemolysin secretion system of 
E. coli which was used in numerous preclinical studies for delivery of pathogen 
derived (112) or tumour associated antigens (114,115) with Salmonella vaccines. Our 
group already demonstrated that HlyA secretion was functional in Ty21a and potent 
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humoral immune responses were elicited against the heterologous HlyA antigen in 
mice (159).  
In this part of the work, the improvement of S. typhi Ty21a for hemolysin expression 
and secretion was described. In a first trial, it was shown that Ty21a is less efficient in 
expression and secretion of HlyA from plasmid pANN202-812 compared to other 
Salmonella vaccines (Figure IV.19). Different mutations account for attenuation of 
Ty21a of which galE and rpoS were supposed to have effects on hemolysin 
secretion. In contrast to galE, it was demonstrated that rpoS was involved in this 
process and complementation with pRpoS harbouring the Stm homolog of rpoS led 
to increase in expression and secretion of HlyA (Figure IV.21). It was speculated 
earlier in this work that RpoS exerts its action on HlyA via rfaH, a factor downstream 
of rpoS which regulates length of the O-side chain of LPS in S. typhi (192). RfaH also 
enhances elongation of Escherichia coli hlyCABD mRNA most likely via 
antitermination (193). For this reason the effect of rpoS on rfaH, hlyA and hlyD 
mRNAs was investigated. However, transcript levels of hlyD and rfaH were highly 
variable in Ty21a pANN202-812 pRpoS when comparing different experiments 
(Figure IV.22). The reason for this is not known but rpoS regulates various genes 
with in parts unknown functions in Salmonella (256) that could also influence 
expression and secretion via T1SS.  
Complementation with pRfaH in the hemolysin-expressing strain Ty21a pANN202-
812 strain showed a highly increased expression and secretion of hemolysin 
compared to the same strain without rfaH plasmid (Figure IV.23 A). Furthermore, 
hlyA transcript levels were doubled when pRfaH was present. This is not surprising 
as the RfaH protein not only acts as antiterminator but also enhances transcription 
initiation at the hly promoter (193,257). This 2-fold increase of hlyA was also 
observed when rpoS was reconstituted via plasmid pRpoS (Figure IV.22). 
Interestingly, pRfaH exhibited a rather slight effect on hlyD transcript which was only 
visible in the logarithmic growth phase (Figure IV.23 B). This is explainable as the 
effect of plasmid pRfaH on rfaH mRNA level weakened at the end of bacterial growth 
(Figure IV.23 B). Furthermore, Ty21a possesses a functional rfaH copy which may be 
sufficient for effective antitermination in the stationary phase, even though it could not 
be regulated by rpoS due to the rpoS-negative phenotype of Ty21a.  
Finally, Ty21a pANN202-812 pRfaH induced significantly higher antibody titres 
against HlyA than control strains and even Ty21 pANN202-812 pRpoS in C57Bl/6 
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mice immunized intranasally. (Figure IV.25). This was unexpected as the latter strain 
also showed increased expression and secretion of HlyA (Figure IV.21). One 
possible reason for this could be improved survival inside macrophages as explained 
in the following. 
Ty21a complemented with rfaH exhibited a higher titre of intracellular bacteria within 
the first 2 h of infection of RAW cells compared to Ty21a alone. This benefit is lost 
after 4 h because rfaHTy21a does not seem to replicate or the balance between 
killing and replication is shifted towards killing of the bacteria (Figure IV.24 B). The 
reason for this is not known, maybe rfaH mediates increased uptake by macrophages 
and/or increased susceptibility against killing by macrophages. Diametrically opposed 
to this hypothesis is a study by Nagy et al. which demonstrated that an rfaH deletion 
mutant of Salmonella typhimurium displayed increased invasion ability and 
decreased survival inside macrophages (258). However, maybe serovar-specific 
characteristics accounted for this contradictory observation.  
Ty21a complemented with rpoS showed increased intracellular survival in RAW 
macrophages compared to the respective wildtype at 2 and 4 h p.i. (Figure IV.24 A). 
These data correspond to a study by Alam et al. in which a S. typhi rpoS-negative 
strain was more susceptible to intracellular killing by RAW macrophages. This killing 
was dependent on the action of nitric oxide synthetase (195). In contrast to that, a S. 
typhi rpoS deletion mutant showed no such susceptibility to intracellular killing in 
resting THP-I cells, a human acute monocytic leukemia cell line. However, this 
mutant was less cytotoxic than the respective wildtype (259) which indicates that 
RpoS could play a role in the virulence of serovar Typhi strains.  
Furthermore, the observed reduced susceptibility to killing might result in less 
efficient MHC presentation of cytoplasmic or non-secreted antigens, which in turn 
could lead to reduced immunogenicity of the RpoS-positive strain. It was postulated 
earlier that decreased bacterial survival inside macrophages would be expected in 
increased availability of antigenic epitopes within the phagolysosome and 
consequently increased presentation of epitope/MHCII complexes (197). Resistance 
against intracellular killing might explain the lower antibody titres of Ty21a pANN202-
812 pRpoS against the examined antigens (Figure IV.25) since the cytoplasmic 
fraction of hemolysin and LPS of the outer membrane are presumably of limited 
access for recognition when the carrier is not efficiently degraded. Of note, nearly all 
mice with one exception exhibited low antibody titres against the major antigen LPS. 
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This was anticipated due to culture conditions used to prepare Ty21a immunization 
aliquots. Since galactose was lacking in the medium, cells were devoid of full length 
O-antigen which in turn limited immunogenicity of LPS (79,189). 
To rule out that instability of pRpoS accounted for low HlyA antibody titres, RAW cells 
were infected 24 h with strain Ty21a pRpoS and Ty21a pACYC184 as control. All 
colonies retained the CmR phenotype conferred by pRpoS whereas pACYC184 was 
readily lost after passage within macrophages (Table IV.5). A functional rpoS copy 
seems to underlie selective pressure and is therefore stabilized during intracellular 
replication presumably by counteracting nitric oxide. In addition plasmids pRfaH and 
pRpoS harbour the same origin of replication which would argue for at least similar 
stability rates. Taken together, it is unlikely that pRpoS is less stable than pRfaH in 
vivo which would lead to a loss of the beneficial effect on HlyA expression. Highly 
stable replication of pANN202-812 was demonstrated earlier (159). 
 
Interestingly, the rpoS null mutation was inherited from the respective wildtype of 
Ty21a, Salmonella typhi Ty2 (260) and congruent to the presumed role of rpoS in 
virulence, the rpoS-positive Typhi ISP1820 serotype is more virulent in humans than 
Ty2 (261). Additionally, both genes, rpoS and rfaH, contribute to virulence in 
Salmonella typhimurium strains. Mutants of these factors were evaluated as live 
vaccine vectors in several studies (80,262-265). Introduction of these genes into the 
attenuated Ty21a strain might for those reasons increase virulence and affect 
attenuation. However, the exact contribution of rpoS in S. typhi virulence remains 
unclear except for a clear role in fine-tuning of the Vi capsule, balancing 
immunogenicity and adhesion and invasion into target cells (266). Nevertheless, 
Ty21a also lacks Vi antigen expression. Furthermore, the attenuating effect of the 
rfaH mutation in S. typhimurium is mainly due to downregulation of other virulence 
factors by silencing of LPS synthesis genes (258). In contrast, Ty21a represents a 
LPS defective strain resulting in a rough phenotype (78,267). It is therefore tempting 
to assume that overexpression of rfaH in Ty21a will not interfere with safety concerns 
as full LPS synthesis is abrogated downstream of this regulator. 
The present data clearly show that Ty21a pRfaH, secreting heterologous antigens via 
the hemolysin secretion system, allows vaccination against the carrier antigen. The 
feasibility of this system for vaccination against cancer in the murine model was 
demonstrated earlier (114,115). Currently, our group is preparing a Ty21a vaccine 
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based on secretion of a CtxB-PSA fusion protein via the hemolysin system for clinical 
trials (Bergmann, B., Gentschev, I., Kirchgraber, G., Weidmann, V., Meyer, R.S., 
Fischer, B., Fensterle, J., and Rapp, U.R.) and its success will determine the fate of 
cancer vaccines of this type. In future projects, this respective carrier could be 
“upgraded” for cancer immune therapy by rfaH complementation. Indeed, a two 
plasmid-based system is undesirable for a clinical vaccine. Hence, rfaH coupled to an 
active promoter can be incorporated on the antigen-determining plasmid, pMKhly1. 
Or as an alternative, promoters with high transcriptional activity can be integrated 
upstream of the rfaH genomic locus to uncouple this antiterminator from (putative) 
rpoS signalling or other regulation, leading to higher transcription rates in vivo. This 
can be achieved by strong promoters like Ptac, successfully used for antigen 
expression in live vaccines (268) or in vivo activated promoters like nirB (269) and 
dmsA (270) which allow strong transcriptional induction when the carriers localize 
within host cells while decreasing the metabolic burden opposed through growth in 
vitro.  
Reflecting all announced facts, recombinant Ty21a strains, complemented with rpoS-
independent rfaH loci, may form the basis of a novel generation of combination 
vaccines for human use which can be administered orally. 
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VII. Appendix 
VII.1. Units 
 
% per cent 
Å Angstroms 
bp, kb base pairs, kilo base pairs 
°C degree Celsius 
F farad 
g gram 
h hour(s) 
kDa kilo Dalton 
l liter 
M molar [mol l-1] 
m meter 
min minute(s) 
rpm revolutions per minute 
s second(s) 
V Volt 
× g factor of gravity 
 
VII.2. Prefixes 
 
f femto 10-15 
p pico 10-12 
n nano 10-9 
µ micro 10-6 
m milli 10-3 
c centi 10-2 
d deci 10-1 
h hecto 102 
k kilo 103 
M mega 106 
G giga 109 
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VII.3. Abbreviations 
 
aa amino acid(s) 
approx. approximately 
AKP alkaline phosphatase 
Amp  Ampicillin 
AmpR Ampicillin resistance 
APC antigen presenting cell 
BCG Mycobacterium bovis Bacille Calmette-Guerin 
BHI brain heart infusion 
BSA bovine serum albumin 
CFU  colony forming units 
CIAP calf intestine alkaline phosphatase 
Cm Chloramphenicol 
CmR Chloramphenicol resistance 
CTL cytotoxic T-cell 
CtxB cholera toxin subunit B 
DC dendritic cell 
dH2O de-ionized water 
EDTA  ethylene diamine tetraacetic acid 
ELISA enzyme linked immunosorbent assay 
ELISPOT enzyme linked immunospot assay 
Ery Erythromycin 
EryR Erythromycin resistance 
FACS fluorescence activated cell sorting 
FITC fluorescein isothiocyanate 
Flp flipase recombinase 
FRT  flipase recombinase target 
HLA human leukocyte antigen 
HlyAs HlyA secretion signal 
HRP horseradish peroxidase 
IFN interferon 
IgG immunoglobulin G 
IL interleukin 
Kan Kanamycin 
KanR Kanamycin resistance 
LB Luria Bertani 
LBV live bacterial vaccine 
LisTB T and B cell epitope of the p60 protein from Listeria monocytogenes 
Lm Listeria monocytogenes EGDe ∆trpS 
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LPS lipopolysaccharide 
MHC major histocompatibility complex 
MIC minimal inhibitory concentration 
MSZ Institute for Medical Radiation and Cell Research 
NK natural killer cell 
NKT natural killer T-cell 
Novo Novobiocin 
OMVs outer membrane vesicles 
o/n over night 
ops  operon polarity suppressor  
Ova chicken ovalbumin 
OVA ovalbumin CD4 and CD8 epitope 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PE phycoerythrin 
PSA prostate specific antigen 
RTX repeats in toxin 
s.c. subcutaneous 
SDS sodium dodecyl sulphate 
Stm Salmonella enterica serovar Typhimurium aroA SL7207  
StmTC Salmonella enterica serovar Typhimurium aroA ∆tolC SL7207  
TAA tumour associated antigen 
TC tolC deleted 
TCA trichloric acid 
TCR T-cell receptor 
TetR tetracycline resistance 
Th T-helper (cell, response) 
TNF tumour necrosis factor 
Treg regulatory T-cell 
Tris tris (hydroxy methyl) aminomethane 
TS temperature sensitive replication 
Ty21a Salmonella enterica serovar Typhi Ty21a 
Ty21aTC Salmonella enterica serovar Typhi Ty21a ∆tolC 
UDP  uridine diphosphate 
w/o without 
× times 
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VII.4. Publications 
VII.4.1. Articles 
 
Stegmeier, J. F., Polleichtner, G., Brandes, N., Hotz, C., and Andersen, C. (2006) 
Importance of the adaptor (membrane fusion) protein hairpin domain for the 
functionality of multidrug efflux pumps. Biochemistry 45 (34), 10303-10312 
 
Fensterle, J., Bergmann, B., Yone, C. L., Hotz, C., Meyer, S. R., Spreng, S., Goebel, 
W., Rapp, U. R., and Gentschev, I. (2008) Cancer immunotherapy based on 
recombinant Salmonella enterica serovar Typhimurium aroA strains secreting 
prostate-specific antigen and cholera toxin subunit B. Cancer Gene Ther 15 (2), 85-
93 
 
Fueller, J., Becker, M., Sienerth, A. R., Fischer, A., Hotz, C., and Galmiche, A. (2008) 
C-RAF activation promotes BAD poly-ubiquitylation and turn-over by the proteasome. 
Biochem Biophys Res Commun 370 (4), 552-556 
 
Hotz, C., Fensterle, J., Goebel, W., Meyer, S. R., Kirchgraber, G., Heisig, M., Fuerer, 
A., Dietrich, G., Rapp, U. R., and Gentschev, I. (2008) Improvement of the live 
vaccine strain Salmonella enterica serovar Typhi Ty21a for antigen delivery via the 
hemolysin secretion system of Escherichia coli. Int J Med Microbiol accepted 
 
Galmbacher, K., Hotz, C., Heisig, M., Wischhusen, J., Galmiche, A., Bergmann, B., 
Gentschev, I., Goebel, W., Rapp, U. R., and Fensterle, J. Block of tumor growth in an 
experimental breast cancer model by elimination of macrophages with a novel 
attenuated variant of Shigella flexneri. submitted 
 
Hotz, C., Wagner, S., Fensterle, J., Goebel, W., Rapp, U. R., and Gentschev, I. 
Cancer Immunotherapy based on a novel recombinant Salmonella enterica serovar 
Typhimurium strain expressing epitopes of prostate-specific antigen (PSA) in surface 
exposed form. in preparation 
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VII.4.2. Patents 
 
Recombinant bacteria with E. coli hemolysin secretion system and increased 
expression and/or secretion of HlyA, process of manufacturing and uses thereof. 
Patent pending (Z08-02), Æterna Zentaris (Hotz, C, inventor share 35 %) 
 
Attenuated bacteria capable of inducing apoptosis in macrophages, process of 
manufacturing and uses thereof. Patent Pending (Z08-01), Æterna Zentaris (Hotz, C., 
inventor share 5 %)  
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